

1 **BEFORE THE SUPREME COURT OF THE STATE OF NEVADA**

2 ALI PIROOZI, M.D.,

3 Petitioner,

4 v.

5 THE EIGHTH JUDICIAL DISTRICT
6 COURT OF THE STATE OF NEVADA,
7 IN AND FOR THE COUNTY OF
8 CLARK; AND THE HONORABLE
9 JAMES BIXLER, DISTRICT COURT
10 JUDGE,

 Respondent(s),

and

11 TIFFANI D. HURST and BRIAN
12 ABBINGTON, jointly and on behalf of
13 their minor child, MAYROSE LILI-
14 ABBINGTON HURST; MARTIN
15 BLAHNIK, M.D.,

Real Party in Interest.

Supreme Court Case No.:

EJDC Case No. A-10-61672-0
Electronically Filed
Feb 05 2014 01:33 p.m.
Tracie K. Lindeman
Clerk of Supreme Court

16 **RESPONDENT ALI PIROOZI, M.D.'S APPENDIX VOL 1**

19 JOHN H. COTTON, ESQ.
20 Nevada Bar No. 005268
21 E-mail: JhCotton@cdwnvlaw.com
22 CHRISTOPHER G. RIGLER, ESQ.
23 Nevada Bar No. 010730
24 E-mail: CRigler@cdwnvlaw.com
25 COTTON, DRIGGS, WALCH,
26 HOLLEY, WOLOSON & THOMPSON
27 400 South Fourth Street, Third Floor
28 Las Vegas, Nevada 89101
 Attorneys for Respondents Ali Piroozi, M.D.

1 **INDEX TO APPENDIX**

2 **VOLUME 1**

3 **DOCUMENT TITLE**

4 **EXHIBIT**

5 ComplaintAPP 1

6 **VOLUME 2**

7 Defendant Sunrise Hospital and Medical Center, LLC's
8 Motion for Summary JudgmentAPP 87

9 **VOLUME 3**

10 Defendant Piroozi MD's Joinder to Hospital Defendant's Opposition
11 To Plaintiff's Motion for Summary Judgment.....APP 214

12 Defendant Blahnick MD's Joinder to Defendant Sunrise Hospital and
13 Medical Center, LLC's Motion for Summary Judgment.....APP 217

14 Defendant Summerlin Hospital and Medical Center LLC's Reply in
15 Support of It's Motion for Summary Judgment..... APP 220

16 Plaintiffs' Motion in Limine No. 2: Exclude Dr. Conti's Settlement
17 From TrialAPP 282

18 Defendant Piroozi MD's Partial Opposition to the Motion in Limine No. 2
19 (To Exclude Dr. Conti's Settlement From Trial)APP 292

20 Defendant Blahnick MD's Opposition to Plaintiff's Motion in
21 Limine No.2: Exclude Dr. Conti's Settlement From TrialAPP 298

22 **VOLUME 4**

23 Defendant Sunrise Hospital and Medical Center LLC's Opposition
24 To Plaintiffs' Motion in Limine No.2: Exclude Dr. Conti's
25 Settlement From TrialAPP 305

26 Reply Memorandum in Support of Plaintiffs' Motion in Limine No.2
27 Exclude Dr. Conti's Settlement From Trial.....APP 315

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Court Minutes 01-08-14	APP 325
Defendant Piroozi MD's Supplemental Opposition to Plaintiffs' Motion in Limine No.2: and Partial Joinder to Defendant Sunrise's Supplemental Opposition to Plaintiffs' Motion in Limine No.3.....	APP 327
Defendant Martin Blahnick MD's Supplemental Briefing to Opposition to Plaintiffs' Motion in Limine 2: Exclude Dr. Conti's Settlement From Trial, Allocation of Fault and Measure Damages No.2:.....	APP 335
Defendant Sunrise Hospital and Medical Center LLC's Supplemental Opposition to Plaintiffs' Motion in Limine No.2: Exclude Dr. Conti's Settlement From Trial	APP 351
Plaintiff's Supplemental Briefing Regarding Their Motion in Limine.....	APP360
Pre-Trial Order	APP 371

1
2
3 **CERTIFICATE OF MAILING**

4 I HEREBY CERTIFY that, on the 4th day of February 2014, and
5 pursuant to NRCP 5(b), I deposited for mailing in the U.S. Mail a true and correct
6 copy of the foregoing **RESPONDENT ALI PIROOZI, M.D.'S APPENDIX**,
7 postage prepaid and addressed to:

8
9 The Honorable Judge James Bixler
10 The Eighth Judicial District Court
11 Regional Justice Center
12 200 Lewis Avenue
13 Las Vegas, Nevada 89101
14 *Respondent*

Catherine Cortez Masto
Attorney General
Nevada Department of Justice
100 North Carson Street
Carson City, Nevada 89701
Counsel for Respondent

13 *Attorneys for Real Parties in Interest*

14 Robert McBride, Esq.
15 Marie Ellerton, Esq.
16 Mandelbaum, Ellerton & McBride
17 2012 Hamilton Lane
18 Las Vegas, Nevada 89106
19 *Attorneys for Real Parties in Interest*
20 *Martin Blahnik, M.D.*

21 /S/ Gemini Yii

22 An employee of Cotton, Driggs, Walch,
23 Holley, Woloson & Thompson
24
25
26
27
28

CIVIL COVER SHEET

County, Nevada

Case No. _____

(Assigned by Clerk's Office)

XXI V

I. Party Information

Plaintiff(s) (name/address/phone):

TIFFANI HURST LAS VEGAS NV

Defendant(s) (name/address/phone):

SINAI HOSPITAL + MEDICAL CENTER

Attorney (name/address/phone):

ROBERT MONRS 1610 E SAHARA AVE
Rm 119 Las Vegas 89104

Attorney (name/address/phone):

(702) 463-8421

II. Nature of Controversy (Please check applicable bold category and applicable subcategory, if appropriate)☐ Arbitration Requested**Civil Cases**


Real Property	Torts	
<input type="checkbox"/> Landlord/Tenant <input type="checkbox"/> Unlawful Detainer <input type="checkbox"/> Title to Property <input type="checkbox"/> Foreclosure <input type="checkbox"/> Liens <input type="checkbox"/> Quiet Title <input type="checkbox"/> Specific Performance <input type="checkbox"/> Condemnation/Eminent Domain <input type="checkbox"/> Other Real Property <input type="checkbox"/> Partition <input type="checkbox"/> Planning/Zoning	<input type="checkbox"/> Negligence <input type="checkbox"/> Negligence - Auto <input checked="" type="checkbox"/> Negligence - Medical/Dental <input type="checkbox"/> Negligence - Premises Liability (Slip/Fall) <input type="checkbox"/> Negligence - Other	<input type="checkbox"/> Product Liability <input type="checkbox"/> Product Liability/Motor Vehicle <input type="checkbox"/> Other Torts Product Liability <input type="checkbox"/> Intentional Misconduct <input type="checkbox"/> Torts/Defamation (Libel/Slander) <input type="checkbox"/> Interfere with Contract Rights <input type="checkbox"/> Employment Torts (Wrongful termination) <input type="checkbox"/> Other Torts <input type="checkbox"/> Anti-trust <input type="checkbox"/> Fraud/Misrepresentation <input type="checkbox"/> Insurance <input type="checkbox"/> Legal Tort <input type="checkbox"/> Unfair Competition
Probate	Other Civil Filing Types	
<input type="checkbox"/> Summary Administration <input type="checkbox"/> General Administration <input type="checkbox"/> Special Administration <input type="checkbox"/> Set Aside Estates <input type="checkbox"/> Trust/Conservatorships <input type="checkbox"/> Individual Trustee <input type="checkbox"/> Corporate Trustee <input type="checkbox"/> Other Probate	<input type="checkbox"/> Construction Defect <input type="checkbox"/> Chapter 40 <input type="checkbox"/> General <input type="checkbox"/> Breach of Contract <input type="checkbox"/> Building & Construction <input type="checkbox"/> Insurance Carrier <input type="checkbox"/> Commercial Instrument <input type="checkbox"/> Other Contracts/Acct/Judgment <input type="checkbox"/> Collection of Actions <input type="checkbox"/> Employment Contract <input type="checkbox"/> Guarantee <input type="checkbox"/> Sale Contract <input type="checkbox"/> Uniform Commercial Code <input type="checkbox"/> Civil Petition for Judicial Review <input type="checkbox"/> Other Administrative Law <input type="checkbox"/> Department of Motor Vehicles <input type="checkbox"/> Worker's Compensation Appeal	<input type="checkbox"/> Appeal from Lower Court (also check applicable civil case box) <input type="checkbox"/> Transfer from Justice Court <input type="checkbox"/> Justice Court Civil Appeal <input type="checkbox"/> Civil Writ <input type="checkbox"/> Other Special Proceeding <input type="checkbox"/> Other Civil Filing <input type="checkbox"/> Compromise of Minor's Claim <input type="checkbox"/> Conversion of Property <input type="checkbox"/> Damage to Property <input type="checkbox"/> Employment Security <input type="checkbox"/> Enforcement of Judgment <input type="checkbox"/> Foreign Judgment - Civil <input type="checkbox"/> Other Personal Property <input type="checkbox"/> Recovery of Property <input type="checkbox"/> Stockholder Suit <input type="checkbox"/> Other Civil Matters

III. Business Court Requested (Please check applicable category; for Clark or Washoe Counties only.)

- | | | |
|---|--|---|
| <input type="checkbox"/> NRS Chapters 78-88 | <input type="checkbox"/> Investments (NRS 104 Art. 8) | <input type="checkbox"/> Enhanced Case Mgmt/Business |
| <input type="checkbox"/> Commodities (NRS 90) | <input type="checkbox"/> Deceptive Trade Practices (NRS 598) | <input type="checkbox"/> Other Business Court Matters |
| <input type="checkbox"/> Securities (NRS 90) | <input type="checkbox"/> Trademarks (NRS 600A) | |

Date

Signature of initiating party or representative



CLERK OF THE COURT

Robert A. Monks
Nevada Bar #11423
1810 East Sahara Rm. 199
Las Vegas, NV 89104
Telephone: (702) 727-4640
Facsimile: (702) 369-1290

Attorney for Plaintiffs

DISTRICT COURT
CLARK COUNTY, STATE OF NEVADA

TIFFANI D. HURST and BRIAN
ABBINGTON, jointly and on behalf of
their minor child, MAYROSE
LILI-ABBINGTON HURST,

Plaintiffs,

vs.

SUNRISE HOSPITAL AND MEDICAL
CENTER, LLC, MARTIN BLAHNICK,
M.D., ALI PIROOZI, M.D., RALPH
CONTI, M.D. and FOOTHILL
PEDIATRICS LLC,

Defendants.

A - 10 - 616728 - C
XXI V
COMPLAINT (Jury Demanded)

Plaintiffs Tiffani D. Hurst and Brian Abbington, jointly and on behalf of their minor child, MayRose Lili-Abbington Hurst, a minor, hereby complain against Defendants and for causes of action allege as follows:

1. Plaintiffs Tiffani D. Hurst and Brian Abbington are individuals currently residing in Clark County, State of Nevada and are the natural parents of MayRose Lili-Abbington Hurst (hereinafter "MayRose"), a minor child.

2. Defendant Sunrise Hospital and Medical Center LLC (hereinafter "Sunrise Hospital") is a health care facility engaged in the business of providing medical care and services in Clark County, State of Nevada. Upon information and belief Sunrise Hospital employed one of more of the individually-named physicians that provided care and treatment to MayRose during her hospitalization at Sunrise Hospital from May, 2008 through August 2008 and is liable for the acts and/or omissions of said agents and/or employees as more specifically described herein.

3. Upon information and belief, Defendant Martin Blahnick, M.D. is a neonatologist licensed to practice medicine in the State of Nevada and, at all times relevant hereto, provided medical care and services to MayRose in Clark County, State of Nevada.

4. Upon information and belief, Defendant Ali Piroozi, M.D. is a neonatologist licensed to practice medicine in the State of Nevada and, at all times relevant hereto, provided medical care and services to MayRose in Clark County, Nevada.

5. Defendant Foothills Pediatrics LLC (hereinafter "Foothills Pediatrics") is a business entity engaged in the business of providing medical care and treatment to children in the State of Nevada. At all times relevant hereto, Defendant Conti and/or others was/were employee(s) and/or agent(s) of said facility and provided medical care and treatment to MayRose at this facility.

6. Upon information and belief, Defendant Ralph Conti, M.D., is a pediatrician licensed to practice medicine in the State of Nevada and, at all times relevant hereto, provided medical care and services to MayRose in Clark County, Nevada.

7. The acts and/or omissions giving rise to Plaintiffs claim occurred in Clark County, State of Nevada.

FACTUAL BACKGROUND

8. On or about May 12, 2008, Plaintiff Tiffani D. Hurst (6 ½ months pregnant with her daughter MayRose) was concerned that she might have a bladder infection and went in for testing.

9. Her urinalysis was negative, but fetal monitoring demonstrated that her baby was experiencing heart decelerations for unknown reasons. Plaintiff was admitted and treated with medication. During Plaintiff's second day in the hospital, the baby continued to experience heart decelerations.

10. Accordingly, on May 14, 2008 at 12:06 a.m., MayRose Hurst was delivered via C-section. The Postoperative diagnosis was that the cause of the heart decelerations was a "short umbilical cord."

11. The medical records reflect that "the respiratory effort was delayed 1 min" and CPAP was given for poor respiratory effort. MayRose was intubated and given one dose of surfactant before 1 hour of age and then was immediately extubated. Oxygen was weaned to less than 50% with good SATS and improved respiratory effort after 5 minutes. MayRose's neurologic exam displayed that she had "appropriate strength and tone for gestational age."

12. Following MayRose's birth, her care was transferred to admitting neonatologist Defendant Martin Blahnick, M.D. MayRose's admitting diagnosis to the NICU was hypoglycemia, prematurity, respiratory distress and suspected sepsis.

13. During her stay in the NICU, MayRose required various treatments and medical interventions including, without limitation, blood transfusions as follows: two on May 4, three on May 15, one on May 16, June 7, June 15, June 23, June 25, July 3, July 24 and July 26. In

addition, MayRose had two Reticulyte (Retic) tests demonstrating that MayRose's "Retic" level was well below normal and was continuing to drop prior to her discharge from the hospital.

14. At no time did Defendants Sunrise, Blahnik or Piroozi advise Plaintiffs that Reticulyte tests were performed, the purpose of such tests, or the results of such tests, including the medical significance thereof.

15. Following MayRose's delivery, Plaintiff questioned Defendants Sunrise, Blahnik and Piroozi regarding MayRose's need for transfusions. Defendants explained that MayRose's need for transfusions was the result of "anemia due to prematurity."

16. Notwithstanding MayRose's ongoing need for many blood transfusions and her dramatically abnormal and dropping Retic count, Defendants did nothing to determine the cause for MayRose's low and falling Retic count or obtain a consult from a hematologist. Instead, Defendants Sunrise, Blahnik and Piroozi discharged MayRose on August 2, 2008.

17. On the day of MayRose's discharge, Plaintiff expressed concern about whether her baby was really ready for discharge and was reassured by Defendants that they would not be discharging MayRose if she weren't a healthy baby.

18. With regard to MayRose's "anemia due to prematurity", Defendants told Plaintiffs that it was a common condition for premature babies and was not a cause for concern.

19. Thereafter, Defendants gave Plaintiffs a "Discharge Summary/Instructions" signed by Defendant Ali Piroozi, M.D., one of MayRose's treating neonatologists, and instructed Plaintiff to follow-up with MayRose's pediatrician within 3 days of MayRose's discharge.

20. Plaintiff scheduled an appointment for MayRose with her pediatrician, Defendant Ralph Conti, M.D. on August 5, 2008 and gave Dr. Conti a copy of the Discharge

Summary/Instructions at that time.

21. Plaintiff was not aware of everything ordered in the Discharge Summary/Instructions and was relying upon MayRose's pediatrician to carefully review the Instructions and follow them to the letter.

22. The subject Discharge Instructions required a follow-up CBC, Diff & Retic count test 30 days after discharge. Defendant Conti failed to follow the discharge instructions and did not order the follow-up CBC, Dif and Retic tests within 30 days of MayRose's discharge as ordered in the Discharge Instructions.

23. MayRose next saw Defendant Conti on September 9, 2008 at which time Plaintiff informed Dr. Conti that MayRose had been screaming as if she were in pain. Dr. Conti noted that she had lost weight and discussed with Plaintiff what infant formula could be used to reduce gas. Once again, Dr. Conti failed to order the follow-up CBC, Dif and Retic tests that were ordered in the Discharge Instructions.

24. On both August 5, and September 9, Dr. Conti assessed MayRose as a "well-child."

25. On September 30, 2008, eight weeks following MayRose's discharge from Sunrise, Defendant Conti saw MayRose again when Plaintiff brought her in for a sick visit for a cough and a face rash. Again, Dr. Conti failed to order the CBC, Diff & Retic count tests as required in MayRose's discharge instructions.

26. The following day, on October 1, 2008, Plaintiff brought MayRose in for a well check and she was assessed as being well. Dr. Conti again failed to order the follow-up CBC, Dif and Retic tests, as ordered in the Discharge Instructions.

27. On October 24, 2008, MayRose returned to Defendant Conti's office for another sick

visit. Dr. Conti was unavailable and so MayRose was seen by Dr. Kathleen Weber. Plaintiff told Dr. Weber that she believed MayRose had the flu because her son had thrown up earlier that week.

28. Dr. Weber told Plaintiff that MayRose needed medication to control reflux and that MayRose was constipated. Dr. Weber also told Plaintiff to take MayRose downstairs to Quest Diagnostics to obtain some tests.

29. Dr. Weber did not tell Plaintiff that the tests were for the CBC, Dif and Ret c count which were supposed to have been obtained within 1 month after MayRose's discharge nor did Dr. Weber convey to Plaintiff that there was any urgency in getting the tests done.

30. Nevertheless, Plaintiff went that moment to get the test performed. Unfortunately, Quest would not perform the test and indicated Plaintiff should have been sent to LabCorp for the test.

31. Accordingly, Plaintiff immediately went to LabCorp for the test, but it was closed for the day. Plaintiff returned to LabCorp the next business day (Monday) and was told that they were really backed up and Plaintiff should come back the following morning.

32. Plaintiff took MayRose to LabCorp on Tuesday, October 28 and a blood sample was taken.

33. In the early morning hours of October 29, 2008, MayRose went limp and lethargic and started breathing shallowly. Plaintiff rushed MayRose to Summerlin Hospital, the closest hospital to Plaintiff's home. At the time of her admission, Plaintiff learned that MayRose was in respiratory distress and anemic shock, with a hemoglobin of only 1.5.

34. A CT scan of MayRose's brain was taken upon her admission to the emergency

department at Summerlin Hospital and appeared normal at that time. A follow-up CT scan taken a couple weeks later revealed that MayRose had sustained a significant brain injury in connection with her crash on October 29, 2008.

35. After several weeks of hospitalization at Summerlin, Plaintiff transferred MayRose to Denver Children's Hospital where an MRI of her brain was taken on December 1, 2008. The MRI confirmed that MayRose had sustained a permanent and severe brain injury.

36. During her hospitalization at Denver Children's hospital, it was also discovered that MayRose was suffering from a rare blood disorder known as Diamond Blackfan Anemia that had gone undiagnosed and untreated since the time of her birth. Defendants' failure to diagnose and treat this serious blood disorder ultimately led to MayRose's ill health and systemic crash in late October, 2008 and the brain injury that ensued.

37. Since the diagnosis of MayRose's Diamond Blackfan Anemia and the brain injury resulting therefrom, MayRose has required extensive medical care and treatment and has endured much pain, suffering and debilitation.

38. If this blood disorder had been properly and timely diagnosed and treated, Diamond Blackfan Anemia is a manageable condition and would not have caused and/or contributed to the brain injury sustained by this child.

FIRST CAUSE OF ACTION
NEGLIGENCE (Individual Neonatologist Physicians)

39. The information alleged in paragraphs 1-38 is realleged as if fully set forth herein.

40. Defendants Blahnik and Piroozi owed MayRose Hurst a duty of care to provide her with medical treatment that meets the requisite standards for physicians practicing in the same area of expertise.

41. Defendants Blahnik and Piroozi breached the applicable standards of care in several respects, including without limitation:

- a. Failing to recognize the medical significance of MayRose's low and falling Retic counts and profound anemia and obtain a consult from a hematologist so that proper treatment could be initiated;
- b. Failing to conduct the appropriate tests to determine the cause for MayRose's low and falling Retic counts and profound anemia;
- c. Failing to adequately monitor MayRose's low and falling retic count and profound anemia with serial blood work and appropriate follow-up and treatment;
- d. Failing to obtain an appropriate consult from a hematologist and/or other specialist;
- e. Failing to timely and accurately diagnose and treat MayRose's Diamond Blackfan Anemia;
- f. Failing to advise MayRose's parents of MayRose's low and falling Retic counts and profound anemia and the urgent need for frequent and serial follow-up testing;
- g. Discharging MayRose at a time when she was not stable and had low and falling Retic counts and profound anemia, without an appropriate referral or discharge plan;

- h. Creating a Discharge Plan that did not require follow-up testing/monitoring of MayRose's CBC, Diff and Retic counts for 30 days following her discharge when, at discharge MayRose was requiring transfusions on a weekly basis and her retic count was falling;
- i. Failing to schedule and conduct their own follow-up testing with respect to MayRose's anemia and low and dropping Retic counts;
- j. Failing to refer MayRose to a Hematologist or other appropriate specialist;
- k. Such further and additional failures as may be later identified through the discovery process.

42. As a result of the Defendants' negligence as set forth herein, MayRose sustained permanent injury and disability. Plaintiffs, including MayRose, have also incurred and will continue to incur special and general damages, including without limitation past and future medical expenses, loss of earning capacity and employability, future wage loss, loss of enjoyment of life's activities, pain and suffering and other damages to be established at trial.

SECOND CAUSE OF ACTION NEGLIGENCE—(Pediatrician)

- 43. The information set forth in paragraphs 1-42 is realleged as if fully set forth herein.
- 44. Defendant Conti owed MayRose a duty of care to provide her with medical treatment that meets the requisite standards for physicians practicing in the same area of expertise.
- 45. Defendant Conti breached the applicable standard of care in several respects, including without limitation:
 - a. Failing to carefully review MayRose's Discharge Summary and Instructions and carry out the order requiring a follow-up CBC, Dif and Retic count within 30 days of MayRose's

discharge from Sunrise Hospital;

b. Failing to recognize the urgent need for the CBC, Dif and Retic count test ordered in MayRose's Discharge Summary/Instructions in light of the child's deteriorating condition and illness;

c. Failing to communicate the need for a follow-up CBC, Dif & Retic test with MayRose's parents and inform them why the test was needed and the urgency thereof;

d. Any other deviations that may be discovered through the discovery process.

46. As a result of the Defendant Conti's negligence as set forth herein, MayRose sustained permanent injury and disability. Plaintiffs, including MayRose, have also incurred and will continue to incur special and general damages, including without limitation past and future medical expenses, loss of earning capacity and employability, future wage loss, loss of enjoyment of life's activities, pain and suffering and other damages to be established at trial.

**THIRD CAUSE OF ACTION
NEGLIGENCE-APPARENT AUTHORITY/VICARIOUS LIABILITY
(All Institutional Defendants)**

47. The information set forth in paragraph 1-46 is realleged as if fully set forth herein.

48. Sunrise Hospital and Foothills Pediatrics, by and through their respective agents and/or employees owed a duty of reasonable care to the Plaintiffs, and Defendants breached that duty.

49. Defendants Sunrise Hospital and Foothills Pediatrics are vicariously liable for the negligent acts and/or omissions of their agents and/or employees, committed within the course and scope of their employment and/or agency with said facilities, under the doctrines of respondeat superior and apparent authority.

50. As stated above, Drs. Blahnick, Piroozi and Conti deviated from the standard of care of reasonably trained physicians in the same or similar circumstances.

51. Inasmuch as any one or more of the defendants were employed by these facilities at the time they rendered medical care and/or treatment to MayRose Hurst, said facility is liable for that care and treatment.

52. To the extent that the individual defendants were NOT employed by these facilities at the time they rendered care and treatment to MayRose Hurst, they were acting as agents of the facilities. Under the doctrine of apparent authority, the facilities are liable for the acts and/or omissions of not only their employees, but also their agents.

53. Sunrise Hospital selected and provided the neonatologists that provided care and treatment to MayRose Hurst during her stay at Sunrise Hospital from May 2008 through August 2008. In so doing, Sunrise Hospital held those physicians out as being agents and/or employees of Sunrise Hospital.

54. Defendants Sunrise Hospital and Foothills Pediatrics hold themselves out in the community as a place where patients can find quality health care.

55. Defendants Sunrise Hospital and Foothills Pediatrics advertise their services to the public in such a way that patients can reasonably believe that physicians practicing at said facilities are in fact employees of those facilities.

56. Neither Defendants Sunrise Hospital or Foothills Pediatrics nor Blahnick, Piroozi, or Conti, made any effort to inform Plaintiffs that they are not in fact employees of the facilities where they practice.

57. Defendants Sunrise Hospital and/or Foothills Pediatrics cloaked Drs. Blahnick,

Piroozi, and Conti with such degree of apparent or ostensible agency that Plaintiffs reasonably believed that, while MayRose was being cared for at said healthcare facilities, said physicians were agents and/or employees of the respective facilities while rendering such care.

58. Plaintiffs reasonably relied on the conduct of Sunrise Hospital and Foothills Pediatrics in concluding that Drs. Blahnick, Piroozi and Conti were employees, and/or agents, of one or more of said healthcare facilities.

59. Drs. Blahnick and Piroozi had apparent authority to act on behalf of Sunrise Hospital, and as such, provided medical care to MayRose Hurst as an agent of the hospital.

60. Dr. Conti had apparent authority to act on behalf of Foothills Pediatrics, and, as such, provided medical care to MayRose Hurst as an employee and/or agent of that facility.

61. Defendants Sunrise Hospital and Foothills Pediatrics are responsible for the acts and/or omissions of its agent physicians as well as its employees that caused and/or contributed to MayRose Hurst's injuries and damages.

62. As a direct and proximate result of the negligence of the employees and/or agent-physicians of Sunrise Hospital and Foothills Pediatrics, Plaintiffs, including MayRose Hurst, have suffered injuries and damages as described herein.

63. In accordance with Nevada state law, the Affidavits of experts attesting to the negligence of the Defendants, as well as the harm and injury arising therefrom, are attached hereto as Exhibits A, B and C and incorporated herein by this reference.

WHEREFORE: Plaintiffs PRAY FOR JUDGMENT AGAINST Defendants UNDER THEIR CAUSES OF ACTION AS FOLLOWS:

1. For an award of past and future economic losses;

2. For an award of past and future general damages;
3. For an award of Plaintiffs' costs of court;
4. For an award of pre and post-judgment interest at the maximum rate allowed by law;
5. For such further and additional relief as the Court deems just and proper.

DATED this ____ day of May, 2010.

ROBERT A. MONKS



Robert A. Monks

Attorney for Plaintiffs

JURY DEMAND

Plaintiffs hereby demand a trial by jury in the above-captioned matter.

DATED this 17 day of May, 2010.

ROBERT A. MONKS



Robert A. Monks

Attorney for Plaintiffs

EXHIBIT A

E. Robert Spear, Esq.-(8672)
E. ROBERT SPEAR, PC
818 Gass Avenue
Las Vegas, Nevada 89101
Telephone: (702) 750-0571
Facsimile: (702) 750-0572

Attorneys for Plaintiff

DISTRICT COURT

CLARK COUNTY, STATE OF NEVADA

T. DANIELLE HURST and BRIAN ABBINGTON, individually and on behalf of their minor child, MAYROSE HURST,

Plaintiffs,

vs.

**SUNRISE HOSPITAL AND MEDICAL
CENTER, LLC, MARTIN BLAHNICK,
M.D., ALI PIROOZI, M.D., RALPH
CONTI, M.D. and FOOTHILL
PEDIATRICS LLC.**

Defendants.

**AFFIDAVIT OF
ALAN H. ROSENTHAL, M.D.**

County of Cuyahoga

SS

State of Ohio

Being first duly sworn upon his oath to tell the truth under penalty of perjury, Alan H.

Rosenthal, M.D. hereby deposes and states as follows:

1. I am a physician licensed to practice medicine in the State of Ohio.

2. I am over the age of twenty-one and competent to testify to the matters contained herein based on personal knowledge or knowledge gained through the review of the medical records in this case.
3. I received my medical degree from Case Western Reserve University in 1983 and subsequently completed an Internship in Pediatrics at Mount Sinai Medical Center in Cleveland Ohio in 1985 and a Residency in Pediatric and Adolescent Medicine at the Cleveland Clinic Foundation in Cleveland, Ohio in 1987.
4. I am board-certified in Pediatrics and my certification is current.
5. I have been a Clinical Instructor of Pediatrics at Case Western Reserve University in Cleveland Ohio from 1986 to the present. Currently, I am a Preceptor for Nurse Practitioners from Francis Payne Bolton School of Nursing at Case Western University.
6. I have practiced in the field of Pediatrics for over 23 years. My qualifications to give opinions in this case are more fully set forth in my Curriculum Vitae which is attached as Exhibit A to this Affidavit.
7. In addition to my education, training, and experience, my opinions are also based upon my familiarity with the medical literature and standards of care governing this area of medicine, as well as a review of the medical records in this case, including the following:
 - a. Records from Sunrise Hospital;
 - b. Records from Foothill Pediatrics (MayRose Hurst's pediatrician);
 - c. Records from Summerlin Hospital where MayRose was treated following her

crash;

d. Records from Denver Children's Hospital where MayRose was ultimately diagnosed with Diamond Blackfan Anemia;

e. Select prenatal records; and

f. September 2008 follow-up MRI

8. I was asked to review the care provided to MayRose Hurst by her pediatrician, Dr.

Ralph Conti following her discharge from Sunrise Hospital on August 2, 2008.

9. My opinions in this case are given to a reasonable degree of medical probability.

10. Based upon my experience, education, training, medical expertise, knowledge of the medical literature, applicable standards of care and my review of the medical records in this case, it is my opinion that Ralph Conti, M.D. deviated from the applicable standard of care in the following respects:

a. Failing on multiple occasions to carefully review the Discharge

Orders/Instructions and obtain the CBC, Diff and Retic Count 30 days

following MayRose's discharge from Sunrise Hospital as set forth in the

Discharge Instructions.

11. It is also my opinion that the foregoing deviation from the standard of care was a proximate cause of MayRose Hurst's downward spiraling clinical course and resulting harm and injury.

DATED this 18 day of ^{April} March, 2010.

Alan H. Rosenthal M.D.
Alan H. Rosenthal, M.D.
Affiant

Subscribed and sworn to before me this 18 day of ^{April} ~~March~~, 2010.

Alan J. Ross
NOTARY PUBLIC

My commission expires:

ALAN J. ROSS, ATTORNEY AT LAW
NOTARY PUBLIC - STATE OF OHIO
MY COMMISSION HAS NO EXPIRATION DATE
SECTION 147.03 R.C.

ALAN H. ROSENTHAL, MD

Office:

26900 Cedar Road, Suite 100
Beachwood, Ohio 44122
(216) 831-7337

Home:

23133 Timberlane Drive
Beachwood, Ohio 44122
(216) 291-1122

EDUCATION & TRAINING

THE CLEVELAND CLINIC FOUNDATION, Cleveland, Ohio
Residency - Pediatric and Adolescent Medicine

1985 - 1987

MOUNT SINAI MEDICAL CENTER, Cleveland, Ohio
Internship - Pediatrics

1984 - 1985

CASE WESTERN RESERVE UNIVERSITY, Cleveland, Ohio
School of Medicine
MD Degree - 1983

CASE WESTERN RESERVE UNIVERSITY, Cleveland, Ohio
Bachelor of Arts Degree - 1978, *Phi Beta Kappa, Magna Cum Laude* graduate
Major: Psychology

UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark
Semester abroad

January - June 1976

EMPLOYMENT HISTORY

PEDIATRIC PLACE, INC., Beachwood, Ohio

Private Practice

January 2001 - Present

HILLCREST PEDIATRICS, INC., Mayfield Heights, Ohio

Private Practice

July 1987 - December 2000

OHIO PHYSICAL THERAPY AND SPORTS MEDICINE, Cleveland, Ohio

Medical Director

1987 - 1991

- Provided sports medicine coverage for schools in three-county area representing 52% market share.
- Monday Night Sports Clinics - Serviced 93 schools during calendar year.
- Friday Night Sports Clinics - Hospital-based during football season.
- Saturday Night Sports Clinics - Hospital-based during football season.
- Pre-participation examinations for high school and college athletes. Over 1000 per year.
- Sportsmetrix Performance Enhancement Program.
- Fitness / testing program.
- Student trainer programs.
- Coaches' Sports Medicine Certification Program. Over 1,200 coaches annually.
- High School students in clinic sports medicine careers. Spring and summer.
- Physical Therapy Interns. Year round.
- Pediatric Residents, Rainbow Babies and Children's Hospital, Cleveland, Ohio.
- Podiatric Residents, University Hospital Health System, Richmond Heights, Ohio.

(Continued)

EMPLOYMENT HISTORY (CONTINUED)

MOUNT SINAI MEDICAL CENTER, Cleveland, Ohio Sports Medicine Institute <u>Medical Director</u>	1991 - 1997
BEACHWOOD HIGH SCHOOL, Beachwood, Ohio <u>Team Physician</u>	1985 - 1997
CITY OF BEACHWOOD, Beachwood, Ohio <u>Beachwood City Doctor</u> (Appointed by Mayor Harvey Friedman)	1985 - 1997

LICENSURE

State Medical Board of Ohio
Medical License #35-05-2220, Expiration: 4/1/2006
Board-Certified in Pediatrics - 1987
Recertified in Pediatrics - 1995
Recertified in Pediatrics - 2001, 2009

HOSPITAL AFFILIATIONS

UNIVERSITY HOSPITAL-HEALTH SYSTEMS, Cleveland, Ohio Rainbow Babies & Children's Hospital	1987 - Present
MERIDIA HILLCREST HOSPITAL, Mayfield Heights, Ohio	1987 - Present
MOUNT SINAI MEDICAL CENTER, Cleveland, Ohio	1987 - 2000
MERIDIA EUCLID HOSPITAL, Euclid, Ohio	1987 - 1992

ACADEMIC APPOINTMENTS

CASE WESTERN RESERVE UNIVERSITY, Cleveland, Ohio Clinical Instructor of Pediatrics	1986 - Present
---	----------------

PROFESSIONAL SOCIETIES

American Academy of Pediatrics, Fellow
Ohio Chapter, American Academy of Pediatrics
Northern Ohio Pediatric Society
Academy of Medicine of Cleveland
American Medical Association
American College of Sports Medicine

(Continued)

RESEARCH

CASE WESTERN RESERVE UNIVERSITY, Cleveland, Ohio
School of Medicine, Department of Biochemistry, Dr. Warwick Sakami
Folic Acid Binding Protein.

Rodney Monroy, Alan Rosenthal, Warwick Sakami, *Multiple Folate Binding Proteins*, presented at Biochemistry Symposium, 1979.

EDUCATIONAL ACTIVITIES

UNIVERSITY HOSPITAL HEALTH SYSTEMS, Cleveland, Ohio
Rainbow Babies and Children's Hospital

2001 - 2002

- Lecturer to Interns and Residents.
- Sports Medicine workshops on knee, ankle, and shoulder examinations to Interns and Residents.
- Supervisor for interns and Residents who serve as team physicians for Richmond Heights High School including pre-participation physical examinations and event coverage.

Preceptor for Interns and Residents from Rainbow Babies and Children's Hospital The Cleveland Clinic Foundation, and Akron Children's Hospital in private practice setting (1987 - present).

Preceptor for Third and Fourth year medical students in private practice setting (1987 - 2002)

Preceptor for second year medical students from CWRU School of Medicine in private practice setting.

LECTURES & TEACHING

UNIVERSITY HOSPITAL HEALTH SYSTEM, Cleveland, Ohio
Lecture to Pediatric and Internal Medicine Residents on "Anabolic Steroids in Sports"

June 12, 2002

UNIVERSITY HOSPITAL HEALTH SYSTEM, Cleveland, Ohio
Pediatrics Today
"On-the-Field Evaluation of Head Injuries"

August 28, 2001

JEWISH COMMUNITY CENTER, Beachwood, Ohio
Medical Director / Associate Coordinator

1990

First Special Needs Olympics which has now become an annual event.

NORTHEAST OHIO SYMPOSIUM ON PEDIATRIC SPORTS MEDICINE, Cleveland, Ohio
Course Director
A practical workshop for prevention, detection, and treatment of sports-related medical problems.

April 5, 1990

OHIO INTERSCHOLASTIC ATHLETIC ADMINISTRATION ASSOCIATION, Columbus, Ohio
Presenter
Topic: "Drugs in Sports"

October 8-10, 1989

(Continued)

LECTURES & TEACHING (CONTINUED)

MOUNT SINAI MEDICAL CENTER, Cleveland, Ohio

David Berger Memorial Lecture

September 8, 1989

"Anabolic Steroids: Are they Destroying our Youth?"

MOUNT SINAI MEDICAL CENTER, Cleveland, Ohio

Pediatric Grand Rounds

May 1990

"Head Injuries in Athletes"

MOUNT SINAI MEDICAL CENTER, Cleveland, Ohio

Pediatric Grand Rounds

May 4, 1990

- Gave lecture on Drugs in Sports.
- Gave lecture on Pre-Participation Physical.
- Conducted workshop on examination of muscle strength and flexibility.

DEEPWOOD CENTER, Mentor, Ohio

Received recognition award for involvement as Physician for Special Olympics. 1985 - 1987

MOUNT SINAI SPORTS MEDICINE INSTITUTE, Cleveland, Ohio

1992 - 1997

OHIO PHYSICAL THERAPY AND SPORTS MEDICINE, Cleveland, Ohio

1987 - 1991

Medical Director

Presented lectures to coaches, athletic directors, teachers, athletes and parents at high schools, junior high schools, and colleges throughout Cuyahoga, Lake, Geauga, Ashtabula and Lake Counties.

PERSONAL DATA

Date of Birth: September 6, 1955

Place of Birth: Cleveland, Ohio

Marital Status: Wife-Tammy (Dentist)

Children: Douglas (8/31/91), Hannah (5/4/89), and Jacki (12/6/87)

- Excellent references available upon request -

EXHIBIT B

Attorneys for Plaintiff

CLARK COUNTY, STATE OF NEVADA

AFFIDAVIT OF
MARCUS C. HERMANSEN, M.I.D.

County of Hillsborough) ss
State of New Hampshire)

1

MC#

2. I am over the age of twenty-one and competent to testify to the matters contained herein based on personal knowledge or knowledge gained through the review of the medical records in this case.

3. I received my medical degree from Indiana University School of Medicine in 1977 and subsequently completed a Pediatric Internship and Residency at Milwaukee Children's Hospital in 1980 and a Fellowship in Neonatology at Children's Hospital Medical Center at the University of Cincinnati in 1982.

4. I am board-certified in Pediatrics and Neonatal-Perinatal Medicine.

5. I have been a Clinical Instructor and Assistant and Associate Professor of Pediatrics at various medical schools and universities across the country. From 1997 to the present, I have been an Associate Professor of Pediatrics at Dartmouth Medical School.

6. I have practiced in the field of Pediatrics and Neonatology for over 30 years and have published in textbooks and authored articles for peer-reviewed journals too numerous to mention. My qualifications to give opinions in this case are extensive and more fully set forth in my Curriculum Vitae which is attached as Exhibit A to this Affidavit.

7. In addition to my education, training, and experience, my opinions are also based upon my familiarity with the medical literature and standards of care governing this area of medicine, as well as a review of the medical records in this case, including the following:

- a. Records from Sunrise Hospital;
- b. Records from Foothill Pediatrics (MayRose Hurst's pediatrician);
- c. Records from Summerlin Hospital where MayRose was treated following her crash;
- d. Records from Denver Children's Hospital where MayRose was ultimately diagnosed

with Diamond Blackfan Anemia;

e. Select prenatal records; and

f. September 2008 follow-up MRI

9. I was asked to review the care provided to MayRose Hurst by the neonatologists overseeing her medical treatment while she was in the NICU at Sunrise Hospital following her birth on May 14, 2008 until the time of her discharge on August 2, 2008.

10. My opinions in this case are given to a reasonable degree of medical probability.


11. Based upon my experience, education, training, medical expertise, knowledge of the medical literature, applicable standards of care and my review of the medical records in this case, it is my opinion that the neonatologists caring for MayRose Hurst following her birth, namely Martin Blahnik, M.D. and Ali Piroozi, M.D. deviated from the applicable standard of care in the following respects:

a. Failing to obtain a hematology consult while MayRose was at Sunrise hospital or, in the alternative, failing to refer MayRose Hurst to a hematologist immediately upon discharge; and

b. Creating a discharge plan that failed to provide for any follow-up blood work sooner than 30 days following her discharge.

12. It is also my opinion that the foregoing deviations from the standard of care were a proximate cause of MayRose Hurst's eventual crash and resulting brain injury.

DATED this 18 day of March, 2010


Marcus C. Hermansen, M.D.
Affiant

Subscribed and sworn to before me this 18th day of March, 2010.

Robert A. Belmore
NOTARY PUBLIC Robert A. Belmore

My commission expires: 12/3/2013



Marcus C. Hermansen, M.D.

Curriculum Vitae

Address:

Office: Southern New Hampshire Medical Center
Nashua, NH 03061
1-603-577-2609
Fax: 1-603-883-5951
E-mail: Marcus.Hermansen@SNHMC.org

Home: 14 Gregg Road
Lovewell Farm
Nashua, NH 03062
1-603-883-5955
E-mail: DoubleThis@Gmail.com

Personal History:

Birth date: September 14, 1952

Birthplace: Rensselaer, Indiana

Undergraduate Education:

1969 DePauw University
1970-1974 Purdue University (Bachelor of Science)

Graduate and Post-graduate Education:

1973-1977 Indiana University School of Medicine (Doctor of Medicine)

1977-1980 Pediatric Internship and Residency
Milwaukee Children's Hospital
The Medical College of Wisconsin
Milwaukee, Wisconsin

1980-1982 Neonatology Fellowship
Children's Hospital Medical Center
University of Cincinnati
Cincinnati, Ohio

September, 2009

Specialty Board Certification:

1982	American Board of Pediatrics
1983	American Board of Pediatrics Sub-Board of Neonatal-Perinatal Medicine

Medical Licensure:

Active:	New Hampshire
Inactive:	Indiana, Kentucky, Ohio, Pennsylvania, Virginia, and Wisconsin

Medical Staff Appointments:

Lexington, Kentucky

1982-1986	Albert B. Chandler Hospital University of Kentucky Medical Center
1983-1986	Humana Hospital of Lexington (consulting staff)

Pittsburgh, Pennsylvania

1986-1995	Allegheny General Hospital
1986-1992	St. Francis Medical Center
1986-1990	Shadyside Hospital (consulting staff)
1987-1991	Forbes Health Systems (consulting staff)
1988-1992	North Hills Passavant Hospital (consulting staff)

Newport News, Virginia

1994-1997	Riverside Regional Medical Center
-----------	-----------------------------------

Nashua, New Hampshire

1997-current	Southern New Hampshire Medical Center
1998-current	St. Joseph's Hospital (consulting staff)
2007-2008	Catholic Medical Center (Manchester, New Hampshire)

Academic Appointments:

1980	The Medical College of Wisconsin Clinical Instructor of Pediatrics
1981-1982	University of Cincinnati College of Medicine Clinical Instructor of Pediatrics
1982-1986	University of Kentucky College of Medicine Assistant Professor of Pediatrics
1988-1995	The Medical College of Pennsylvania Associate Professor of Pediatrics

Academic Appointments (continued):

- 1995-1997 Medical College of Virginia
Clinical Instructor of Obstetrics and Gynecology
- 1997-current Dartmouth Medical School
Associate Professor of Pediatrics
Adjunct Associate Professor of Obstetrics and Gynecology

Awards:

- 1982 Frederick M. Kenny Memorial Award in Pediatric Research,
Midwest Society for Pediatric Research, Chicago
- 1998-1999 Excellence in Teaching, Department of Obstetrics and
1999-2000 Gynecology, Dartmouth Medical School
- 2006 Southern New Hampshire Health System Physician Champion
<http://www.snhmc.org/archives/02-10-06.htm>

Professional Societies:

- 1983-current American Academy of Pediatrics
1984-current - Section on Perinatal Pediatrics
1985-1993 - Section on Computer Technologies
1983-1994 National Perinatal Association
1983-1986 Southern Perinatal Association
1983-1986 American Association for Medical Systems and Informatics
1984-1985 Southern Society for Pediatric Research
1984-1986 American Federation for Clinical Research
1985-1996 Study Group for Complication of Perinatal Care
1985-1986 Society for Computers in Pediatric Research
1986-2000 Midwest Society for Pediatric Research
1987-1994 Pennsylvania Perinatal Association
1987-1994 Pittsburgh Pediatric Society
1997-current New England Association of Neonatologists
1997-current New Hampshire Pediatric Society
1997-2003 New Hampshire Conflict Resolution Association (formerly the
New Hampshire Mediation Association)

Institutional Committees and Appointments:

University of Kentucky Medical Center

1983-1986 Pharmacy and Therapeutics Review Committee

1985-1986 Transfusion Review Committee

St. Francis Medical Center

1986-1987 Director of Neonatology

1986-1987 Intensive Care Committee

1986-1987 Bio-ethics Committee

Shadyside Hospital

1987-1990 Director of Newborn Services

Allegheny General Hospital

1987-1994 Director of Neonatology

1987 Advances in Perinatal and Neonatal Medicine, Program Director

1987-1989 Nursing Research Committee

1989-1992 Physician Liaison Committee

1991-1993 Cardio-Pulmonary Resuscitation Subcommittee

1991 Environmental Scan Group: Health Care Indicators

1992 Acting Chairman of Pediatrics

1993-1994 Pastoral Care Advisory Committee

1993-1994 Pediatrics Quality Assurance Czar

1993 Corporate Management Committee

1993 Executive Committee of the Medical Staff

1994 Pediatric Nutritional Support Team

1994 Pediatric CPR Committee

1994 Ad hoc Committee on the Multi-disciplinary Care of Infants with Cleft Lip/Cleft Palate, Chair

Medical College of Pennsylvania

1993 Department of Pediatrics Chair Search Committee

1993-1994 Medical Student Residency Advisor

Riverside Regional Medical Center

1994-1996 Director of Newborn Services

1994-1996 Bio-ethics Committee

1994-1996 Pediatrics Quality Assurance Committee

1994-1996 Clinical Resource Management Initiative

1995-1996 OB/GYN Nurse/Physician Liaison Committee

1995-1996 Pharmacy and Therapeutics Committee

Institutional Committees and Appointments (continued):Southern New Hampshire Medical Center

1997-current Director of Neonatology
 1997-current Neonatal Intensive Care Unit Committee, Chairman
 1997 Vermont Oxford Network, Participating Investigator
 1997-current Maternal-Child Health Council
 1997-current Principle Investigator for the Boston University Pregnancy Health Interview Study at Southern New Hampshire Medical Center
 1998-2005 Continuing Medical Education Committee
 1998-current Ethics Committee
 1998-2000 Y2K Task Force
 1998-1999 Medical Partners Foundation Leadership Task Force
 1998-2000 Foundation Information Systems Advisory Group
 1999-current Director of the Pediatric Hospitalist Program
 1999-2000 Chairman of Pediatrics
 1999 Executive Committee of the Medical Staff
 1999 Community Medical School, faculty
 1999-current Credentials Committee (Chair 2008-current)
 2001-2003 Vice-Chairman of Pediatrics
 2001-2002 Electronic Medical Records Committee
 2005-current Breastfeeding Practice Committee
 2008-current Medical Executive Committee
 2008-current Professionals Health Committee

Non-Institutional Committees and Appointments:

1984-1987 Chairman, Sub-Committee on Hospital Based Computer Systems, Section on Computers and Other Technologies, American Academy of Pediatrics
 1985-1986 Consulting Physician for "Baby Doe" Investigations, Kentucky Cabinet for Human Resources, Department of Social Services
 1985-1986 Chairman, Committee on Computers, Kentucky Chapter, American Academy of Pediatrics
 1985-1986 Liaison for the Kentucky Chapter and the Section on Computers of the American Academy of Pediatrics
 1986 Neonatal Nutritional Software Focus Group, Ross Laboratories, Columbus, Ohio
 1986 Rood and Riddle Equine Hospital, consultant
 1987-1989 Legislative Committee, Pennsylvania Perinatal Association
 1988 Program Coordinator, Pittsburgh Regional Neonatology Forum
 1988-1990 Advisory Board, Peer Review Resources
 1989-1992 Medical and Research Advisory Committee, The Pittsburgh Zoo
 1990-1996 Neonatal Resuscitation Program Regional Trainer
 1990-current Neonatal Resuscitation Program Provider
 1990-1996 Question writer for the American Board of Pediatrics Neonatal-Perinatal Medicine Board Examination

Non-Institutional Committees and Appointments (continued):

1991-1992	Editorial Board of Critical Reading: Understanding and Evaluation Studies in Cardiology
1992-1994	Editorial Board of Perspectives on Medical Research
1994-1996	Consultant for the Statistical Assessment Action Task Force for the SunHealth Alliance
1997-2002	Mediator for the City of Nashua, New Hampshire
1999-current	Pediatric Advanced Life Support (PALS) provider
2001	New Hampshire Medical Society representative to the New Hampshire Young Inventor's Program
2001-2004	New Hampshire State Birth Defects Surveillance System Advisory Committee
2002	Case reviewer for the New Hampshire Board of Medicine
2002, 2003	United Way of Nashua Community Investment Committee – Children and Dependent Needs
2002	Credentialing Consultant to Anthem Blue Cross and Blue Shield
2003-2008	NICU-NET Moderator
2005-2007	Consultant to the Nashua Police Department
2005-current	Physician volunteer for the New Hampshire Malpractice Screening Panels
2007-2009	Consultant to the Association of Women's Health, Obstetric and Neonatal Nurses (AWHONN)
2007-current	Permedion Independent Medical Reviewer

Manuscript Reviewer:

Advances in Neonatal Care
 American Journal of Diseases of Childhood
 American Journal of Obstetrics and Gynecology
 American Journal of Perinatology
 Archives of Disease in Childhood
 Haematologica
 Journal of Pediatrics
 Journal of Postgraduate Medicine
 Obstetrics and Gynecology
 Pediatrics
 Pediatrics International

Additional Clinical Experience:

Western lowland gorilla (*Gorilla gorilla gorilla*) newborns
 Thoroughbred (*Equus caballus*) foals
 Bongo antelope (*Tragelaphus eurycerus*) calves
 Reticulated giraffe (*Giraffa camelopardalis*) calves
 Alpaca (*Lama pacos*) crias
 Leopard (*Geochelone pardalis*) and Indian Star (*G. elegans*) tortoise hatchlings
 Bantam chicken (*Gallus gallus*) chicks

Books:

1. **Hermansen M:** Biostatistics: Basic Concepts Caduceus Medical Publishers, Patterson, NJ 1990
2. **Hermansen MC:** Guest Editor, Risk Management in Neonatal-Perinatal Medicine. Clinics in Perinatology, Vol. 32, No. 1, March, 2005. ISBN 1-4160-2754-8.
http://www.elsevier.com/wps/find/bookdescription.cws_home/705386/description#description
3. **Hermansen MC:** Guest Editor, Perinatal Etiologies of Cerebral Palsy. Clinics in Perinatology, Vol. 33, No. 2, June, 2006. ISBN 1-4160-3543-5.
http://www.elsevier.com/wps/find/bookdescription.cws_home/708200/description#description
4. **Hermansen MC:** Guest Editor, Iatrogenic Disease. Clinics in Perinatology, Vol. 35, No. 1, March, 2008. ISBN 1-4160-5798-6.
http://www.elsevier.com/wps/find/bookdescription.cws_home/714306/description#description

Book Chapters:

1. Perlstein P, Edwards N, Atherton H and **Hermansen M:** Computer-assisted Environmental Control for Newborns. In Harris TR and Bahr JP (eds.): The Use of Computers in Perinatal Medicine Praeger Scientific, New York, Chapter 21, pp 363-373, 1982
2. **Hermansen M:** Thrombocytopenia and Platelet Dysfunction. In Gomella TL and Cunningham MD (eds.): Neonatology: Basic Management, On-Call Problems, Diseases, Drugs McGraw-Hill, New York.
1st Edition: pp 201-204, 1988
2nd Edition: pp 270-274, 1991
3rd Edition: pp 278-281, 1994
3. **Hermansen M:** Hydrocephalus. In Gomella TL and Cunningham MD (eds.): Neonatology: Basic Management, On-Call Problems, Diseases, Drugs McGraw-Hill, New York.
1st Edition: pp 292-294, 1988
2nd Edition: pp 377-379, 1991
3rd Edition: pp 383-385, 1994

Book Chapters (continued):

4. **Hermansen M:** Intraventricular Hemorrhage. In Gomella TL and Cunningham MD (eds.): Neonatology: Basic Management, On-Call Problems, Diseases, Drugs McGraw-Hill, New York.
1st Edition: pp 294-296, 1988
2nd Edition: pp 379-382, 1991
3rd Edition: pp 385-387, 1994
5. **Hermansen M and Cunningham MD:** Management of the Extremely Low Birth Weight Infant during the First Week of Life. In Gomella TL and Cunningham MD (eds.): Neonatology: Basic Management, On-Call Problems, Diseases, Drugs McGraw-Hill, New York.
2nd Edition: pp 105-113, 1991
6. **Hermansen MC, Menkes JH and Sarnat HB:** Neonatal Neurology. In Menkes JH and Sarnat HB (eds.): Child Neurology 8th Edition. Lippincott Williams and Wilkins, Philadelphia. In press.

Original Articles

1. Blankenbaker R, **Hermansen M**, Steele G and Hall JH: Total Care the Cost-Effective Way. In New Concepts in Health, Proceedings of the Twelfth Annual Meeting of the Society of Prospective Medicine. Health and Education Resources, Bethesda, Maryland, pp 103-107, 1977
2. **Hermansen MC**, Starshak RJ and Werlin SL: Caroli Disease: The Diagnostic Approach. *Journal of Pediatrics* 1979; 94:879-92.
3. **Hermansen MC**, Chusid MJ and Sty JR: Bacterial Epididymo-orchitis in Children and Adolescents. *Clinical Pediatrics* 1980; 19:812-5.
4. Starshak RJ, Sty JR, **Hermansen MC** and Werlin SL: Diagnosis of Caroli Disease. *Journal of Pediatrics* 1980; 96:344.
5. **Hermansen MC**, Starshak RJ and Werlin SL: Diagnosis of Caroli Disease. *Journal of Pediatrics* 1980; 97:330.
6. **Hermansen MC** and Blodgett FM: Prospective Evaluation of Routine Hospital Admission Urinalyses. *American Journal of Diseases of Children* 1981; 135:125-30.
7. **Hermansen MC** and Ellison PH: Cerebrospinal Fluid Acid-Base Balance in Newborns. *Annals of Neurology* 1982; 11:334-6.

Original articles (continued):

8. **Hermansen M**, Atherton H, Edwards N and Perlstein P: The Evaluation of a Computer Generated Blood Gas Display in a Newborn Intensive Care Unit. Proceedings of the Second Cleveland Symposium on Computers in Perinatal Medicine, 2:112, 1982
9. **Hermansen MC**, Kotagal U and Kleinman L: The Effect of Metabolic Acidosis upon Autoregulation of Cerebral Blood flow in Puppies. Syllabus of the Second Special Ross Laboratories Conference on Perinatal Intracranial Hemorrhage, pp 48-59, 1982
10. **Hermansen MC**, Perlstein PH, Atherton HD and Edwards NK: A Computer Generated Blood Gas Display in a Newborn Intensive Care Unit. *Journal of Pediatrics* 1983; 102:825-8.
11. **Hermansen MC**: Water Supplementation in Breast-fed Infants. *Pediatrics* 1983; 103:499-500.
12. **Hermansen MC**, Perlstein PH and Edwards NK: A Baffling Case of Hypothermia. *The Lancet* 1984; 1:40-41.
13. **Hermansen MC** and Johnson GL: Neonatal Supraventricular Tachycardia Following Prolonged Maternal Ritodrine Administration. *American Journal of Obstetrics and Gynecology* 1984; 149:798-9.
14. **Hermansen MC**, Kotagal U and Kleinman L: The Effect of Metabolic Acidosis upon Autoregulation of Cerebral Blood Flow in Newborn Dogs. *Brain Research* 1984; 324:101-5.
15. **Hermansen MC** and Sullivan LS: Feeding Intolerance Following the Ophthalmologic Examination of Neonates. *American Journal of Diseases of Children* 1985; 139:367-8.
16. **Hermansen MC** and Hasan S: Abolition of Feeding Intolerance Following Ophthalmologic Examination of Neonates. *Journal of Pediatric Ophthalmology and Strabismus* 1985; 22:256-7.
17. **Hermansen MC** and Hasan S: Inaccurate Recording of Birth Weight of Premature Infants. *Journal of Perinatology* 1986; 6:14-5.
18. **Hermansen MC**, Mooney L and Hines C: Light and Transcutaneous pO_2 Device = Problem? *Pediatrics* 1986; 77:788-789.
19. **Hermansen MC** and Hasan S: The Importance of Using Standardized Birth Weight Increments to Report Neonatal Mortality Data. *Pediatrics* 1986; 78:144-5.

Original articles (continued):

20. **Hermansen MC, Kahler K and Kahler B:** Date Entry Errors in Computerized Nutritional Calculations. *Journal of Pediatrics* 1986; 109:91-3.
21. **Hasan S and Hermansen M:** The Prenatal Diagnosis of Ventral Abdominal Wall Defects. *American Journal of Obstetrics and Gynecology* 1986; 155:842-5
22. **Hermansen MC and Buches M:** Super Diapers and Premature Infants. *Pediatrics* 1987; 79:1056-1057.
23. **Gilmore R, Brock J, Hermansen MC and Baumann R:** Development of Lumbar Spinal Cord and Cortical Evoked Potentials After Tibial Nerve Stimulation in Pre-Term Newborns: Effects of Gestational Age and Other Factors. *Electroencephalography and Clinical Neurophysiology* 1987; 68:28-39.
24. **Hermansen MC and Hasan S:** An Evaluation of a Computer Program to Predict the Outcome of Hyaline Membrane Disease. *American Journal of Perinatology* 1987; 4:249-52.
25. **Hermansen MC, Hasan S, Hoppin J, and Cunningham MD:** A Validation of a Scoring System to Evaluate the Condition of Very-Low-Birthweight Neonates. *American Journal of Perinatology* 1988; 5:74-8.
26. **Hermansen MC and Buches M:** Urine Output Determination from Superabsorbent and Regular Diapers under Radiant Heat. *Pediatrics* 1988; 81:428-31.
27. **Hermansen MC:** Intrapartum Asphyxia and Cerebral Palsy. *Pediatrics* 1989; 83:653-654.
28. **McKay JG, Hermansen MC and Maley BE:** Diminished Splenic Function in Asphyxiated Term Infants. *Journal of Perinatology* 1990; 10:12-5.
29. **Hermansen M:** Avoid Common Pitfalls in Retrospective and Prospective Studies. *Critical Reading* 1991; 1(1):13-14.
30. **Hermansen M:** Risk Factors: When to Worry About the Reliability of Data. *Critical Reading* 1991; 1(2):13-14.
31. **Hermansen MC and Barnhart MC:** Evaporation from Reusable Cloth Diapers Exposed to Radiant Heat. *Journal of Perinatology* 1992; 12:72-2.
32. **Hermansen MC and Prior MM:** Oxygen Concentrations from Self-Inflating Resuscitation Bags. *American Journal of Perinatology* 1993; 10:79-80.

Original articles (continued):

33. Jasnosz KM, Hermansen MC, Snider C and Oh KS: Congenital Complete Absence (Bilateral Agenesis) of the Diaphragm: A Rare Variant of Congenital Diaphragmatic Hernia. *American Journal of Perinatology* 1994; 11:340-3.
34. Goetz MC, Gretebeck RJ, Oh KS, Shaffer D and Hermansen MC: Incidence, Timing, and Follow-up of Periventricular Leukomalacia. *American Journal of Perinatology* 1995; 12:325-7.
35. Hermansen MG and Hermansen MC: The Influence of Equipment Weights on Neonatal Daily Weight Measurements. *Neonatal Network* 1999; 18:33-6.
36. Hermansen MC: Nucleated Red Blood Cells as a Marker of Acidemia in Term Neonates. *American Journal Obstetrics and Gynecology* 2000; 182:1645.
37. Hermansen MC: Umbilical Cord Blood Gases, Casebook VIII. *Journal of Perinatology* 2000; 20:450-1.
38. Hermansen MC: Nucleated Red Blood Cells in the Fetus and Newborn. *Archives of Diseases in Childhood – Fetal and Neonatal Edition* 2001; 84:F211-5.
39. Hermansen MC: Potential for Brief but Severe Intrapartum Injury among Neonates with Early-onset Seizures and Elevated Nucleated Red Blood Cell Counts. *American Journal Obstetrics and Gynecology*, 2001; 184:782.
40. Hermansen MC: Keeping Kernicterus in Check. *AAP News*, 2001:19:22.
41. Hermansen MC: The Acidosis Paradox: Asphyxial Brain Injury without Coincident Acidemia. *Developmental Medicine and Child Neurology*, 2003; 45:353-6.
42. Hermansen MC: Umbilical Cord Blood Gases. *Journal of Perinatology*, 2004; 24:563-4.
43. Hermansen MC: Asphyxial Brain Injury without Acidemia: Reply. *Developmental Medicine and Child Neurology*, 2004:46:431.
44. Hermansen MC: Risk Management in Neonatal-Perinatal Medicine. *Clinics in Perinatology*, 2005; 32: xiii-xiv.
45. Hermansen MC and Hermansen MG: Pitfalls in Neonatal Resuscitation. *Clinics in Perinatology*, 2005; 32:77-95.
46. Hermansen MC and Hermansen MG: Intravenous Catheter Complications in the Neonatal Intensive Care Unit. *Clinics in Perinatology*, 2005; 32:141-56.

Original articles (continued):

47. **Hermansen MC:** The Southern New Hampshire Medical Center Neonatal-Pediatric Hospitalist Program. <http://media.wiley.com/assets/1032/02/072005.pdf> *The Hospitalist*, 2005; 9(4):55-56
48. **Hermansen MC and Vitterito JA:** Medical Malpractice in Perinatal Medicine. eNeonatal Review by Johns Hopkins University School of Medicine. Vol. 3, No 5 Jan. 2006. <http://www.hopkinscme.org/ofp/eneonatalreview/Newsletters/0106.html>
49. **Hermansen MC:** Perinatal Causes of Cerebral Palsy. *Clinics in Perinatology*, 2006; 33: xv-xvi.
50. **Hermansen MC and Hermansen MG:** Perinatal Infections and Cerebral Palsy. *Clinics in Perinatology*, 2006; 33:315-333.
51. **Hermansen MC:** Primum non nocere. *Clinics in Perinatology*. 2008;35:xv-xvi.

Abstracts:

1. **Hermansen MC and Blodgett FM:** Routine Hospital Admission Urinalysis. *Pediatric Research* 1979; 13:413.
2. **Hermansen MC, Kordus BJ, Bahr JP, Grausz JP and Hanus MJ:** Computerized Medical Records in a Neonatal Intensive Care Unit. *Pediatric Research* 1980; 14:515.
3. **Hermansen MC and Ellison PH:** Cerebrospinal Fluid Acid-Base Regulation in Newborns. *Pediatric Research* 1981; 15:709.
4. **Hermansen MC, Perlstein PH and Edwards NH:** Incubator Humidity with Different Humidity Reservoir Baffle Systems. *Pediatric Research* 1981; 15:633.
5. **Hermansen MC, Atherton H, Edwards N, Phillips D and Perlstein P:** The Effect of a Computer Generated Blood Gas Display on the Outcome of RDS. *Pediatric Research* 1982; 16:185A.
6. **Hermansen M, Kotagal U and Kleinman L:** Effect of Metabolic Acidosis upon Autoregulation of Cerebral Blood Flow in Puppies. *Clinical Research* 1982; 30:711A.
7. **Hermansen MC, Kotagal U and Kleinman L:** Effect of Metabolic Acidosis upon Autoregulation of Cerebral Blood Flow in Puppies. *Pediatric Research* 1983; 17:364A.

Abstracts (continued):

8. **Hermansen MC and Sullivan LS:** Feeding Intolerance and Necrotizing Enterocolitis Following the Ophthalmologic Examination of Neonates. *Clinical Research* 1983; 31:910A.
9. **Hermansen MC and Sullivan LS:** Feeding Intolerance Following Ophthalmologic Examination of Neonates. *Pediatric Research* 1984; 18:153A.
10. **Hermansen MC:** A Computer-Generated Blood-Gas Display in a Newborn Intensive Care Unit. *Update: Computers in Medicine* 1984; 2:33-34.
11. **Hermansen MC and Hasan S:** Evaluation of a Computerized Model of Hyaline Membrane Disease. *Clinical Research* 1984; 32:888A.
12. **Hermansen M, Kahler R and Kahler B:** Computerized Nutritional Support in a Newborn Intensive Care Unit. *Clinical Research* 1984; 32:888A.
13. **Carr WA, Baumann RJ, Walsh JW, Hermansen MC and Lee C:** NMR Imaging in Infants and Children with Neurological Disorders. *Annals of Neurology* 1984; 16:408.
14. **Gilmore RL, Hermansen MC, Brock J and Baumann RJ:** Effect of Sleep on Cortical SSEP: Age Dependency during Growth and Development. *Electroencephalography and Clinical Neurophysiology* 1985; 61:18P.
15. **Gilmore RL, Brock J, Hermansen MC and Baumann RJ:** Assessment of Lumbar Spinal Cord and Early Cortical Evoked Potentials after Tibial Nerve Stimulation during the Neonatal Period: Effects of Conceptual Age and Body Length. *Electroencephalography and Clinical Neurophysiology* 1985; 61:18P.
16. **Hermansen MC and Hasan S:** The Outcome of Pregnancies with Prenatal Diagnosis of Ventral Abdominal Wall Defects. *Clinical Research* 1986; 34:257A.
17. **Hermansen MC, Hasan S and Cunningham MD:** Validation of a Scoring System to Evaluate the Condition of Transported Preterm Neonates. *Clinical Research* 1986; 34:244A.
18. **McKay JG, Hermansen MC and Maley BE:** Documentation of Hyposplenism in Asphyxiated Term Infants. *Clinical Research* 1986; 34:258A.
19. **Hermansen MC, Hasan S and Cunningham MD:** Validation of a Scoring System to Evaluate the Condition of Transported Preterm Neonates. *Pediatric Research* 1986; 20:379A.

Abstracts (continued):

20. McKay JG, Hermansen MC and Maley BE: Documentation of Diminished Splanchnic Function in Asphyxiated Term Infants. *Pediatric Research* 1986; 20:392A.
21. Hermansen MC and Hasan S: The Evaluation of a New Gestational Age Examination for Infants Less than 30 Weeks Gestation. *Pediatric Research* 1987; 21:396A.
22. McKay JG, Cunningham MD, Hermansen MC, Dickey KM and Dickson LG: The Effect of Leukocyte Transfusion on Pulmonary Compliance and Resistance in Term Pups with Pneumonia. *Pediatric Research* 1987; 21:418A.
23. Hermansen M, Karamchandani N and Groose C: Pneumograms in Infants of Maternal Methadone Users. *Clinical Research* 1987; 35:910A.
24. Hermansen M, Moore W, Waller A and Hodges S: Neonova Nutritional Optimizer™: Software to Provide Computerized Nutritional Support for Infants in Neonatal Intensive Care Units. American Academy of Pediatrics Annual Meeting Program, pages 7-8.
25. Hermansen MC and Goetz M: Point-of-care Blood Gas Testing in a Neonatal Intensive Care Unit. *Journal of Investigative Medicine (Supplement)* 1995; 43:493A.

Scientific Presentations, Invited Lectures and Visiting Professorships:

1. Routine Hospital Admission Urinalyses. American Pediatric Society/Society for Pediatric Research, Atlanta, May, 1979
2. Good Samaritan Hospital, Cincinnati, Perinatology Grand Rounds, "Neutropenia and Neonatal Sepsis", March, 1981
3. Evaluation of a Computerized Blood Gas Display. Second Annual Meeting on Perinatal Data Systems, Milwaukee, September, 1981
4. University of Kentucky Medical Center, Lexington, "Neonatal Sepsis and Granulocyte Transfusions", November, 1981
5. The Evaluation of a Computer Generated Blood Gas Display in a Newborn Intensive Care Unit, Second Cleveland Symposium on Computers in Perinatal Medicine. Cleveland, May, 1982
6. The Effect of Metabolic Acidosis upon Autoregulation of Cerebral Blood Flow in Puppies. Midwest Society for Pediatric Research, Chicago, November, 1982

Scientific Presentations, Invited Lectures and Visiting Professorships (continued):

7. A Computer Generated Blood Gas Display. Computers in Pediatrics, Denver, November, 1982
8. Feeding Intolerance and Necrotizing Enterocolitis Ophthalmologic Examination of Neonates. Southern Society for Pediatric Research, New Orleans, January, 1994
9. Ross Laboratories, Columbus, Ohio, "Computerized Nutritional Support", April, 1984
10. Nuclear Magnetic Resonance Imaging of Infants. Lake Barkley Conference on Perinatal Research, Cadiz, Kentucky, May, 1984
11. An Evaluation of a Computerized Model for Hyaline Membrane Disease. American Association for Medical Systems and Informatics, Washington, November, 1984
12. Computerized Nutritional Support in a Newborn Intensive Care Unit. Southern Society for Pediatric Research, New Orleans, January, 1985
13. Evaluation of a Computerized Model of Hyaline Membrane Disease. Southern Society for Pediatric Research, New Orleans, January, 1985
14. Clinical Applications of a Computerized Database. American Academy of Pediatrics, Atlanta, March, 1985
15. The Medical College of Ohio, Toledo, "Hyperbilirubinemia - A 1985 Update", December, 1985
16. Metropolitan General Hospital, Cleveland, "Research Evaluations of Computer Applications in Perinatal Medicine", December, 1985
17. Validation of a Scoring System to Evaluate the Condition of Transported Preterm Neonates. Southern Society for Pediatric Research, New Orleans, February, 1986
18. Mary Breckenridge Hospital, Hyden, Kentucky, "Polycythemia", February, 1986
19. University of Kentucky Medical Center, Lexington, Division of Neurosurgery, Department of Surgery, "An Introduction to Bio-Statistics", Spring, 1986
20. University of Kentucky Medical Center, Lexington, Department of Radiation Medicine, "An Introduction to Bio-Statistics", Spring, 1986
21. Validation and Application of a Scoring System to Evaluate the Condition of Transported Preterm Neonates. Midwest Regional Conference on Neonatal Transport, Columbus, October, 1986

Scientific Presentations, Invited Lectures and Visiting Professorships (continued):

22. Perinatology-Neonatology 1986: Compromised Fetus, Perinatal Problems, and High-Tech Neonatology sponsored by the University of Michigan Medical School, Ann Arbor, "Magnetic Resonance Imaging", October, 1986
23. Children's Hospital of Pittsburgh, Pittsburgh, "Gestational Age Evaluation of the Fetus and Neonate", December, 1986
24. Children's Hospital of Pittsburgh, Pittsburgh, "An Introduction to Bio-Statistics", March, 1987
25. Children's Hospital of Pittsburgh, Pittsburgh, "Apgar Scores: A Predictor?", June, 1987
26. West Virginia University Medical Center, Morgantown, Pediatric Grand Rounds, "Gestational Age Determinations", August, 1987
27. Magee Women's Hospital, Pittsburgh, "Drug Withdrawal in Newborns", September, 1987
28. Children's Hospital of Pittsburgh, Pittsburgh, "An Introduction to Bio-Statistics", Fall, 1988
29. NeoNova Nutritional Optimizer. American Academy of Pediatrics, San Francisco, October, 1988
30. Twelfth Annual Lake Barkley Conference on Perinatal Research, Lake Barkley, Kentucky, May, 1988
31. Mead-Johnson Nutritional Division, Evansville, "A Pediatric Educational Program in Bio-Statistics", February, 1989
32. Michigan Conference on Maternal and Perinatal Health, Dearborn, "Magnetic Resonance Imaging in Neonatal/Perinatal Medicine" and "Are Apgar Scores Still Worthwhile" March, 1989
33. University of Kentucky Medical Center, Lexington, "Does Birth Asphyxia Cause Brain Damage?", May, 1990
34. The Medical College of Pennsylvania, Philadelphia, "Birth Asphyxia and Brain Damage", June, 1990
35. Perinatal Biostatistics, Denver, "Pitfalls in Information Collection, Recording, and Interpretation for the Neonatal Database", November, 1991

Scientific Presentations, Invited Lectures and Visiting Professorships (continued):

36. University of Pittsburgh Graduate School of Public Health, Pittsburgh, "Infant Mortality and the Neonatal Intensive Care Unit", January, 1992
37. West Virginia University Medical Center, Morgantown, "Selecting the Correct Statistical Test" and "Common Mistakes in the Use of Bio-Statistics", July, 1993
38. University of Pittsburgh Graduate School of Public Health, Pittsburgh, "Infant Mortality and the Neonatal Intensive Care Unit", January, 1994
39. InPhyNet Medical Director's Winter Workshop, Ft. Lauderdale, "Neonatal Resuscitation", March, 1995
40. Dartmouth-Hitchcock Medical Center, Lebanon, NH, "Periventricular Leukomalacia", October, 1997
41. New England Fall Nursing Conference, Salem, NH, "Anemia of Prematurity" and "Neuro-Developmental Outcomes", October, 1998
42. Vermont/New Hampshire Regional Perinatal Program, Lebanon, NH, "Neonatal Intracranial and Extracranial Bleeding: A Case Study", May, 1999
43. Dartmouth-Hitchcock Medical Center, Lebanon, NH, "Fifty Years of Apgar Scores", October, 1999
44. 14th Annual Neonatal Critical Care Conference. Dartmouth-Hitchcock Medical Center, Lebanon, NH, "Birth Asphyxia: Manifestations, Treatment and Outcomes", October, 2000
45. Concord Hospital, Concord, New Hampshire. "Neonatal Abstinence Syndrome", October, 2001
46. 15th Annual Neonatal Critical Care Conference. Dartmouth-Hitchcock Medical Center, Lebanon, NH, "Birth Asphyxia: Manifestations, Treatment and Outcomes", November, 2001
47. Wentworth-Douglas Hospital, Dover, New Hampshire. "Neonatal Abstinence Syndrome", December, 2001
48. Dartmouth-Hitchcock Medical Center, Lebanon, NH, "Re-emergence of Kernicterus", January, 2002
49. Dartmouth-Hitchcock Medical Center, Lebanon, NH, "The Acidemia Paradox", January, 2003

Scientific Presentations, Invited Lectures and Visiting Professorships (continued):

50. Elliot Hospital Conference on "Supporting Neurological Development", Manchester, NH, "Birth Asphyxia: Clinical Manifestations, Treatments, and Outcomes", November, 2003
51. Neonatal Critical Care: The Basics and Beyond. Dartmouth-Hitchcock Medical Center, Lebanon, NH, "Common Resuscitation Errors: Strategies for Improving Your Likelihood of Success", November, 2004
52. Northern New England Perinatal Quality Improvement Network and the American College of Obstetricians and Gynecologists Conference: Preventing Injury during Delivery: A Response to the JCAHO Sentinel Alert. Fairlee, Vermont, "Managing and Simulating OB Emergencies: Non-Reassuring Fetal Status", May, 2005
53. Workshop on Perinatal-Neonatal Arterial Stroke. National Institutes of Health (NIH), National Institute of Child Health and Human Development (NICHD), and National Institute of Neurological Disorders and Stroke (NINDS). Bethesda, August, 2006 (PEDIATRICS Vol. 120 No. 3 September 2007, pp. 609-616)
54. St. Joseph Hospital, Nashua, New Hampshire. "Neonatal Abstinence Syndrome", November, 2006
55. New England Fall Nursing Conference, Tyngsboro, MA. "Birth Injury: The Earliest Signs", November, 2006
56. Dartmouth-Hitchcock Medical Center, Lebanon, NH, "Interpretation of Umbilical Cord Blood Gases", June, 2007

EXHIBIT C

E. Robert Spear, Esq. (8672)
E. ROBERT SPEAR, PC
818 Gass Avenue
Las Vegas, Nevada 89101
Telephone: (702) 750-0571
Facsimile: (702) 750-0572

Attorneys for Plaintiff

DISTRICT COURT

CLARK COUNTY, STATE OF NEVADA

T. DANIELLE HURST and BRIAN)
ABBINGTON individually and on behalf of)
their minor child, MAYROSE LILI-)
ABBINGTON HURST,)

Plaintiffs,)

vs.)

SUNRISE HOSPITAL AND MEDICAL)
CENTER, LLC, MARTIN BLAHNICK,)
M.D., ALI PIROOZI, M.D., RALPH)
CONTI, M.D. and FOOTHILL)
PEDIATRICS LLC,)

Defendants.)

AFFIDAVIT OF
KATHLEEN SAKAMOTO, M.D

County of _____)

State of California)

Being first duly sworn upon her oath, Kathleen Sakamoto, M.D. hereby deposes and states
as follows:

1. I was asked to review this case and provide opinions pertaining to the medical care that was provided to MayRose Lili-Abbingtion Hurst ("MayRose") following her birth in May, 2008, as it relates to the cause of her subsequent crash and brain injury in late October/early November 2008. I have personal knowledge regarding the information contained herein and could and would be willing to testify regarding the same if called upon to do so.

2. I received my medical degree from the University of Cincinnati, College of Medicine in 1985 and subsequently completed an Internship and Residency in Pediatrics at the Children's Hospital of Los Angeles.

3. Thereafter, I completed a Fellowship in Hematology/Oncology at the Children's Hospital of Los Angeles in 1989. I am Board-Certified in General Pediatrics and Pediatric Hematology-Oncology and my certifications are current.

4. From 1991-1993, I was a Clinical Instructor in the Division of Hematology-Oncology, Department of Pediatrics, UCLA School of Medicine. Thereafter, I was a visiting Assistant and Assistant Professor of Pediatrics in the Division of Hematology-Oncology, Department of Pediatrics, UCLA School of Medicine.

5. Beginning in 2005 to the present, I have been Chief of the Division of Hematology-Oncology, Mattel Children's Hospital UCLA, David Geffen School of Medicine. From 2006 to the present, I have been the Vice-Chair of Research, Mattel Children's Hospital, David Geffen School of Medicine at UCLA and Co-Associate Director of Signal Transduction Program Area, Jonsson Comprehensive Cancer Center.

6. From 2008 to the present, I have been a Professor, Chief and Director of the Pediatric Hematology/Oncology Fellowship Program, Mattel Children's Hospital- UCLA.

7. I am also a member of the Scientific Advisory Board to the Diamond Blackfan Anemia Foundation. I have specific expertise regarding this particular blood disorder. My qualifications to give opinions in this case are extensive and more fully set forth in my Curriculum Vitae which is attached as Exhibit A to this Affidavit.

8. In addition to my education, training, and experience, my opinions are also based upon my familiarity with the medical literature and standards of care governing this area of medicine, as well as a review of the medical records in this case, including the following:

- a. Records from Sunrise Hospital;
- b. Records from Foothill Pediatrics (MayRose's pediatrician);
- c. Records from Summerlin Hospital where MayRose was treated following her crash;
- d. Records from Denver Children's Hospital where MayRose was ultimately diagnosed with Diamond Blackfan Anemia;

e. Select prenatal records; and

f. September 2008 follow-up MRI

9. My opinions in this case are given to a reasonable degree of medical probability.

10. Based upon my experience, education, training, medical expertise, knowledge of Diamond Blackfan Anemia, the medical literature, applicable standards of care and my review of the medical records in this case, I have formed the following opinions:

a. MayRose Hurst should have been provided with a hematology consult prior to her discharge from Sunrise Hospital;

b. At the very least, MayRose Hurst should have been referred to a hematologist for follow-up care or earlier and more frequent visits to the Pediatrician for blood counts at the time of

her discharge from Sunrise Hospital;

c. Based upon MayRose's condition and presentation in the NICU at Sunrise hospital, including her need for repeated transfusions, her significant anemia, her low and falling reticulocyte count, and her apparent lack of response to traditional therapies, a hematologist would have conducted appropriate diagnostic studies (including bone marrow tests) that more likely than not would have diagnosed MayRose's blood disorder and treatment for that condition, to include close monitoring of Hg level and regular red cell transfusions, would have been immediately implemented.

d. At a minimum, serial blood work would have been conducted on this child following discharge on a weekly basis initially to monitor her hemoglobin and reticulocyte count and ensure that her hemoglobin did not fall below 6 grams/dl.

e. The care and treatment that would have been provided to this child by a hematologist if one had been consulted would have resulted in the timely and proper diagnosis, monitoring and treatment of MayRose Hurst's blood disorder.

f. The failure to properly diagnose, monitor and treat MayRose Hurst's blood disorder resulted in significant anemia with Hg of 2 grams/dl, which was, more likely than not, contributory to and one of the proximate causes of the acute and life-threatening illness she developed as well as her ensuing complications.

DATED this 11 day of March, 2010.

Kathleen Sakamoto, M.D., Ph.D.
Kathleen Sakamoto, M.D., Ph.D.
Affiant

Subscribed and sworn to before me this 11 day of March, 2010.

My commission expires:

NOTARY PUBLIC

JURAT

State of California


County of LOS ANGELES

Subscribed and sworn to (or affirmed) before me on this 11

day of MARCH, 2010, by _____

KATHLEEN SAKAMOTO

proved to me on the basis of satisfactory evidence to be the person s)
who appeared before me.



(Seal)

Signature

Betty Y. Tang

CURRICULUM VITAE

KATHLEEN MIHO SAKAMOTO, M.D., Ph.D.

PERSONAL HISTORY

WORK ADDRESS Mattel Children's Hospital UCLA
Division of Hematology-Oncology
10833 Le Conte Avenue
Factor 11-234
David Geffen School of Medicine
Los Angeles, CA 90095-1752

PHONE NUMBERS Phone: 310/794-7007 (office) or 310/206-5626 (lab)
Fax: 310/206-8089

EMAIL ADDRESSES kms@ucla.edu or ksakamoto@mednet.ucla.edu

CITIZENSHIP United States

EDUCATION

1975-1979 Williams College, Williamstown, MA; B.A. Cum Laude; Biology
1981-1985 University of Cincinnati, College of Medicine, Cincinnati, OH; M.D.
1985-1986 Internship, Pediatrics, Children's Hospital of Los Angeles
1986-1988 Residency, Pediatrics, Children's Hospital of Los Angeles
1988-1989 Fellowship, Hematology/Oncology, Children's Hospital of Los Angeles
2000-2003 California Institute of Technology, Pasadena, CA; Ph.D. Biology
Howard Hughes Medical Institute, Laboratory of Raymond J. Deshaies

LICENSURE

1986 California License, G58328
1994 DEA license, BS1361992

BOARD CERTIFICATION

1986 Diplomate, National Board of Medical Examiners
1989 Diplomate, American Board of Pediatrics (recertified 1999, 2005)
1994 Diplomate, American Board of Pediatrics, Hematology-Oncology (recertified 1999, 2006)

RESEARCH INTERESTS

Mechanisms of Leukemogenesis
Mechanisms of Bone Marrow Failure
Novel therapeutic approaches to treat cancer

PROFESSIONAL EXPERIENCE

1991-1993 Clinical Instructor, Division of Hematology-Oncology, Department of
Pediatrics, UCLA School of Medicine

1993-1994	Visiting Assistant Professor of Pediatrics, Division of Hematology-Oncology, Department of Pediatrics, UCLA School of Medicine
1994-1998	Assistant Professor of Pediatrics, Division of Hematology-Oncology, Department of Pediatrics, UCLA School of Medicine
1995-present	Joint appointment, Department of Pathology and Laboratory Medicine
1998-2003	Associate Professor of Pediatrics and Pathology, Mattel Children's Hospital at UCLA, UCLA School of Medicine
2003-present	Professor of Pediatrics and Pathology & Laboratory Medicine
2004-2009	Visiting Associate, Division of Biology, California Institute of Technology
2005-present	Professor of Pediatrics and Pathology & Laboratory Medicine, David Geffen School of Medicine at UCLA
2005-present	Chief of Division of Hematology-Oncology, Mattel Children's Hospital, David Geffen School of Medicine at UCLA
2006-present	Vice-Chair of Research, Mattel Children's Hospital, David Geffen School of Medicine at UCLA
2006-present	Co-Associate Director of Signal Transduction Program Area, Jonsson Comprehensive Cancer Center
2008-present	Pediatric Hematology/Oncology Fellowship Program Director, Mattel Children's Hospital UCLA

RESEARCH EXPERIENCE

1978-1979	Senior Honors Thesis, Department of Biology, Williams College. "Effects of Centrifugation Time on Separation of Plant Organelles".
1979-1980	Research Assistant, Department of Biochemical Genetics, City of Hope Medical Center
1993-1996	Research Assistant, Department of Physiology, USC School of Medicine,
1980-1991	Postdoctoral Fellow, Division of Hematology-Oncology, in the laboratory of Judith C. Gasson, Ph.D., UCLA School of Medicine
1999	Visiting Associate, laboratory of Raymond Deshaies, Ph.D., Department of Biology, California Institute of Technology, Pasadena, CA.
2000-2004	STAR program/Graduate Studies, Division of Biology, Laboratory of Raymond Deshaies, PhD, Howard Hughes Medical Institute, California Institute of Technology, Pasadena, CA.

PROFESSIONAL SOCIETY MEMBERSHIPS

Candidate Fellow, American Academy of Pediatrics
 Member, American Society of Hematology
 Member, American Society of Pediatric Hematology-Oncology
 Member, American Association for Cancer Research
 Member, New York Academy of Science
 Member, Western Society for Pediatric Research
 Member, Society for Pediatric Research
 Member, International Society for Experimental Hematology
 Children's Oncology Group, AML Strategy Group
 American Society for Biochemistry and Molecular Biology (ASBMB)
 Member, Los Angeles County Medical Association

COMMITTEES ON CAMPUS

1994	Search Committee for Director of the Jonsson Cancer Center
1995	Search Committee for Nephrology Faculty Appointment
1996-1998	Admissions Committee, UCLA ACCESS program for graduate students
1996-1999	Admissions Committee, Medical Student Training Program, UCLA
1994-present	UCLA Cancer Committee
1998-1999	Chair of Tumor Cell Biology ACCESS Affinity Group for Graduate Students
1996-2002	Western Society for Pediatric Research (WSPR) Council member
2002-present	Search Committee for Pediatric Pulmonary
2002-present	Search Committee for Pediatric Nephrology
2002-present	Search Committee for Pediatric Hematology-Oncology
2006	Search Committee for Pediatric Cardiology
2006	Search Committee for Infectious Disease
2006	Committee for Loan Repayment, Department of Pediatrics
2006	Search Committee for Biostatistician, Department of Pediatrics
2006	Chair, Search Committee for Neonatology
2006-present	Pediatric Credentials Committee
2007	Member, Coordinating Committee for CNSI-CNBI Symposium on NanoBiotechnology
2008	Executive committee, California Nanosystems Institute (CNSI) UCLA
2008-present	Membership committee, CNSI-CNBI, UCLA
2008-present	Search Committee, Pediatric Surgery
2008-present	Quality Assurance committee, David Geffen School of Medicine
2008-2011	Admissions Policy Subcommittee, David Geffen School of Medicine
2008-present	AMWA Mentorship Program, David Geffen School of Medicine
2009-present	Keyser Endowed Chair Search Committee
2009-present	Pathology Search Committee for Faculty Position in B-ALL

CAMPUS ACTIVITIES

1994-present	Faculty Mentor on the Medical Student Training Program
1994-present	Principal Investigator on the Tumor Cell Biology Training Grant
1995	Faculty Advisor Program for first year medical students
1995-present	Principal Investigator on the UCLA ACCESS program for graduate Students
2007-present	Organize the Pediatric Fellows Core Curriculum noon seminars, Science Day
2007-present	Organize the Basic Science Journal Clubs for Residents
2007-present	Organize the Pediatric Translational Research Program (seed grant, grant mentors, core equipment, symposium, seminar series)
2006-present	Organize seminars, lunch/business meetings, and roundtable discussions for the Jonsson Comprehensive Cancer Center
2007-present	Organizer for Hematopoiesis Journal Club for Jonsson Cancer Center with Program areas in Signal Transduction, Hematologic Malignancies, and Gene Regulation

EDITORIAL BOARD/REVIEWER

Editorial board: Stem Cells, Blood

Medical Editor, emedicine online textbook for Pediatrics (Hematology-Oncology section)

Current Drugs, panel of evaluators

Ad hoc reviewer for journals: Ad hoc reviewer for journals: Oncogene, Proceedings of the National Academy of Sciences, Molecular and Cellular Biology, Journal of Cellular Biochemistry, Leukemia, Biotechniques, Cytometry, Pediatric Research, Cancer Research, Molecular Cancer Therapeutics, American Journal of Hematology, Molecular Genetics and Metabolism, American Journal of Human Genetics, New England Journal of Medicine, Pediatric Blood and Cancer, Cancer Research, Clinical Cancer Research, British Journal of Hematology, Clinical Prostate Cancer, Pediatrics, Cancer Letters, Journal of Pediatric Hematology-Oncology.

Teaching

1993-present	Pediatric Hematology-Oncology elective
1993-present	Advanced Clinical Clerkship in Pediatric Hematology-Oncology
1993-present	Laboratory course in Biochemistry for first year medical students
1993-present	Pediatric Clerkship
1993-present	Advanced Clinical Clerkship in Pediatrics
1995	Ethics and Accountability in Biomedical Research
1995-1997	Major Concepts in Oncology
1995	Molecular and Cellular Foundations of Disease
1993-1997	Organization of Pediatric Hematology-Oncology weekly clinic conferences
1995-1999	Organization of the Pediatric Departmental Monthly Research Seminars
1999-2004	M229 Course on Cell Biology and Pathogenesis for ACCESS Graduate Students on "Cell Cycle" (organized by Patricia Johnson)
1996-2003	Pathophysiology Course in Hematopathology (session on Lymphoma)
2005	MBI 298 seminar course on Ubiquitination
2005-present	Co-organizer, M294 Pathology course on Molecular Basis of Oncology
2009-present	Director of M270 course on Developmental Hematology

Clinical Activities

1993-present	Medical Staff, Pediatric Hematology-Oncology, UCLA School of Medicine and Santa Monica Hospital
--------------	---

COMMUNITY SERVICE

2007-2008 Leukemia and Lymphoma Society of America, Los Angeles Chapter, Board of Trustees and Executive Board

PATENTS

"Proteolysis Targeting Chimeric Pharmaceutical" (Raymond Deshaies, Craig Crews, and Kathleen Sakamoto), Ref. No. CIT3284.

HONORS AND SPECIAL AWARDS

1988	Victor E. Stork Award, Children's Hospital of Los Angeles
1990-1993	Leukemia Society of America Fellowship Award
1991	Leukemia Society of America award as First Designated Researcher supported by the Leukemia Society staff
1992-1995	Jonsson Comprehensive Cancer Center/STOP CANCER Career Development Award
1996-2002	Leukemia Society of America Special Fellow Award
1994	Young Investigator Award in Oncology, American Society for Pediatric Hematology-Oncology
1995	UCLA Frontiers of Science Award
1996	Ross Award in Research By Young Investigators (Western Society for Pediatric Research)
1998-2003	Leukemia Society of America Scholar Award
1998	Elected Council Member, Western Society for Pediatric Research
1998	Participant, AAMC Workshop for Senior Women in Academic Medicine
1999	Invited Participant, American Cancer Society Professors Meeting, October, New York
1997	"Meet-the-Expert", Signal Transduction and Cell Cycle Control in Myeloid Cells, American Society of Hematology, New Orleans, LA
1998	Katherine E. Rogers Scholar for Excellence in Cancer Research, Jonsson Comprehensive Cancer Center, UCLA
1999	Member of Scientific Review Committee, CONCERN Foundation
2000	AACR-Novartis Scholar in Training Award, Oncogenomics meeting, Tucson, AZ
2001	Keystone Symposium on "Cell Cycle" - Travel Award, Keystone, CO.
2002	AACR-AFLAC Scholar-in-Training Award, meeting on Ubiquitination and Cancer meeting, Vancouver, Canada.
2002	Full member, Molecular Biology Institute, UCLA
2003-present	Children's Oncology Group, Myeloid Biology Subcommittee
2003-2007	Member, Grant Review Subcommittee on Leukemia, Immunology, and Blood Cell Development for American Cancer Society
2004	NIH Study Sections on Drug Discovery and Molecular Pharmacology and Basic Mechanisms of Cancer Therapy, and Special Emphasis Panel on Diamond-Blackfan Anemia and Bone Marrow Failure syndromes
2004	Grant Reviewer, UC Discovery Biotechnology Program
2004	Moderator, Leukemia Session at American Society for Pediatric Hematology-Oncology Annual Meeting
2004	Abstract Reviewer and Moderator for "Hematopoiesis: Regulation of Gene Transcription," ASH Meeting
2005-2009	Member, NIH Hematopoiesis Study Section
2004	Grant Reviewer, Susan G. Komen Breast Cancer Foundation
2005	"Ask the Experts" in Pediatric Cancer, AACR Public Forum, Anaheim, CA.
2005	Chair of Minisymposium, Modulation of Protein Stability. AACR, Anaheim, CA.

2005-present	Member, Translation Research Program Review Subcommittee for the Leukemia and Lymphoma Society of America
2005	Moderator, Pediatric Hematology-Oncology session, PAS/ASPHO meeting, Washington DC, May 2005
2005-2009	Grant Reviewer, California Research Cancer Committee (CRCC)
2005-2009	Member, ASH Scientific Committee on Myeloid Biology
2006	Reviewer, NIH Oncology Postdoctoral Fellowship Committee
2006-present	CDMRP (DOD) CML Grant Review Committee
2006	ASH abstract reviewer on "Hematopoiesis: Regulation of Gene Transcription" for annual meeting
2006	UCLA Finalist, Margaret Early Trust Award
2006	Benjamin Franklin High School Wall of Fame Award
2006	Member, American Pediatric Society
2007	Abstract Coordinating Reviewer, ASH meeting 2007
2007	<u>Stem Cells</u> journal Lead Reviewer Award
2007	Nominated for Who's Who in America
2007	Best Doctors in America
2008-present	Member, ASH Myeloid Biology Subcommittee
2008	"Meet the Expert" Transcription Factors in Myelopoiesis, ASH meeting
2008-present	Maryland Stem Cell Exploratory Grant Peer Review Committee
2009	NY Stem Cell Grant Peer Review Committee
2008	NIH Special Emphasis Panel/CRG Loan Repayment Program Review Committee
2008	Chair of Cancer Committee, America's Best Children's Hospital, U.S. News & World Report
2008	Pediatric Cancer Research Foundation "Gift of Hope" Award
2008	Who's Who and Super Doctors of Southern California
2009	America's Top Doctors in Cancer
2009	Fernbach Distinguished Visiting Professor Lectureship, Texas Children's Hospital, Baylor College of Medicine
2010	Board of Trustees, American Society of Pediatric Hematology/Oncology
2010-2011	Vice Chair and Chair of the Myeloid Subcommittee, American Society of Hematology

RESEARCH GRANTS AND FELLOWSHIPS

1989-1990	American Cancer Society Clinical Oncology Fellowship
1990-1993	5 F32 CA08974-04 Individual National Research Service Award Molecular Analysis of Target Cell Response to Human GM-CSF (\$102,100); National Cancer Institute (Judith Gasson, Ph.D., P.I.)
1996-2002	Fellowship Award, Molecular Characterization of GM-CSF Action (\$70,000) Leukemia Society of America (Judith C. Gasson, Ph.D., P.I.)
1993-1998	K08 CA59463, Clinical Investigator Award, Molecular Characterization of GM-CSF Action (\$383,400), National Cancer Institute (Judith Gasson, Ph.D.)

P.I.)

- 1993-1996 3017-93, Special Fellow Award, Molecular Analysis of GM-CSF Action (\$100,400), Leukemia Society of America (K. Sakamoto, M.D., P.I.)
- 1992-1995 Career Development Award, Molecular Characterization of GM-CSF Action (\$150,000), STOP CANCER (K. Sakamoto, M.D., P.I.)
- 1992-1993 Seed Grant, Mutation Analysis of Structure-Function Relationships of Human GM-CSF Receptor Beta Subunit (\$30,000), Jonsson Comprehensive Cancer Center (K. Sakamoto, M.D., P.I.)
- 1992-1993 Mutation Analysis of Structure-Function Relationships of the Human GM-CSF Receptor Beta Subunit (\$25,000), Southern California Children's Cancer Service and Couples Against Leukemia (declined) (K. Sakamoto, M.D., P.I.)
- 1993-1995 Molecular Regulation of *egr-1* by IL-3 and PIXY321 in Myeloid Leukemia (\$100,000), Concern II (K. Sakamoto, M.D., P.I.)
- 1994 The Role of Cyclins in Myeloid Leukemias (\$25,000), Southern California Children's Cancer Service and Couples Against Leukemia (K. Sakamoto, P.I.)
- 1995 UCLA Academic Senate Award (\$1,500), "Stem Cell Factor Activation of Signal Transduction in Myeloid Leukemic Cells" (K. Sakamoto, M.D., P.I.)
- 1995 UCLA Frontiers of Science Award, The Regulation and Functional Role of p55CDC in Myeloid Leukemias (\$28,000) (K. Sakamoto, M.D., P.I.)
- 1995 UCLA Prime Faculty Research Award, Molecular Regulation of Myeloid Cell Differentiation (\$25,000) (K. Sakamoto, M.D., P.I.)
- 1995 Seed Grant, The Role of SRE-Binding Proteins During Signal Transduction in Myeloid Leukemias (\$27,000), Jonsson Comprehensive Cancer Center (K. Sakamoto, M.D., P.I.)
- 1995 New Assistant Professor Grant, Transcriptional Regulation of *egr-1* by Stem Cell Factor in Myeloid Leukemias (\$35,000), Cancer Research Coordinating Committee (K. Sakamoto, M.D., P.I.)
- 1995-1997 Shannon Award, NIH (NCI) 1R55CA68221, Molecular Regulation of Myeloid Cell Differentiation, (\$80,000) (K. Sakamoto, M.D., P.I.)
- 1996 Concern II Foundation; Molecular Analysis of IL-3 and PIXY321 Signaling Pathways in Myeloid Leukemias (\$50,000) (K. Sakamoto, M.D., P.I.)
- 1996-2002 First Award R29CA68221, Molecular Regulation of Myeloid Cell Differentiation, (\$350,000), NIH/NCI (K. Sakamoto, M.D., P.I.)

- 7/97-6/99 UC Biotechnology STAR Project, S97-03 "p53Cdc and Cell Cycle Regulation" (\$40,000); Amgen, Inc. and University of California (K. Sakamoto, M.D. P.I.)
- 7/98-6/99 Contract with Eli Lilly, Inc. "Multiple Resistance Genes in Leukemias" (\$32,000), Co-PI with Leonard Rome, Ph.D. (K. Sakamoto, M.D., P.I.)
- 7/98-6/99 Jonsson Comprehensive Cancer Center Seed Grant, "Use of Low Molecular Weight Heparin in Cancer Patients Receiving Stem Cell Transplants," (\$10,000), Co-P.I. with Dr. Sinisa Dovat, M.D. (fellow)
- 7/98-6/2003 Leukemia Society of America Scholar Award, 1997-99 "The Role of p53 Cdc during Myelopoiesis" (\$350,000), Leukemia Society of America (K. Sakamoto, P.I.)
- 1/99-12/2001 Investigator initiated grant, California Cancer Research Program, "Cell Cycle Control and Cancer" (\$400,000), California Department of Health Services (K. Sakamoto, P.I.)
- 7/99- 6/2000 Jonsson Comprehensive Cancer Center Seed Grant, "Development of a Novel Class of Protein-inhibiting Anti-cancer Therapeutics" (\$15,000), K. Sakamoto (P.I.) and Raymond Deshaies (Co-P.I., Caltech)
- 1/2000 CaPCURE research award, "Development of a Novel Class of Protein-Inhibiting Therapeutics for Prostate Cancer" (\$100,000). Raymond Deshaies (P.I., Caltech), K. Sakamoto, and Craig Crews (Co-P.I., Yale University).
- 1/99-12/02 Research Project Grant, "Molecular Analysis of Myeloid Cell Proliferation" (\$300,000); American Cancer Society (K. Sakamoto, P.I.)
- 8/01-7/03 UC Biostar, "Targeting the estrogen receptor for Proteolysis", with Celgene, Inc. (\$40,000), K. Sakamoto, P.I.
- 1/02-12/02 CaPCURE research award, "Targeting the Androgen Receptor for Degradation in Prostate Cancer" (\$75,000) K. Sakamoto (P.I.), Raymond Deshaies (Co-P.I., Caltech) and Craig Crews (Co-P.I., Yale University).
- 6/02-7/03 National Cancer Coalition, "Signal Transduction and Cell Cycle Analysis in Leukemia" (\$5,000), K. Sakamoto (P.I.).
- 1/03-12/06 American Cancer Society, Research Scholar Award. "The role of CREB in Leukemogenesis," (\$625,000). K. Sakamoto (P.I.).
- 1/03-6/04 Department of Defense, "Targeting the estrogen receptor for ubiquitination and proteolysis in breast cancer," (\$222,819). K. Sakamoto (P.I.)
- 1/03-12/03 Diamond-Blackfan Anemia Foundation, "AML in Diamond-Blackfan Anemia: Molecular Basis and Therapeutic Strategies," (\$25,000). K. Sakamoto (P.I.)

- 1/1/03-12/31/04 SPORE grant in Prostate Cancer Research, Seed Grant Award, "Targeting the Androgen Receptor for proteolysis in Prostate Cancer," \$ 5,000. K. Sakamoto (P.I.)
- 4/1/03-3/31/04 Stein-Oppenheimer Award, "Targeting the Estrogen Receptor in Breast Cancer," \$20,000. K. Sakamoto (P.I.)
- 6/1/03-5/30/04 Genomic Exploration Seed Grant, Jonsson Comprehensive Cancer Center, "CREB and Human Leukemias," \$5,000, K. Sakamoto (P.I.)
- 7/1/03-6/30/04 Susan G. Komen Breast Cancer Thesis Dissertation Award," \$20,000. K. Sakamoto, R. J. Deshaies (P.I.)
- 1/04-12/08 NIH/NHLBI R01 (HL 75826), "The Role of CREB in Leukemogenesis," (\$200,000/year). K. Sakamoto (P.I.)
- 9/04-8/08 R21, "Ubiquitination and Degradation in Cancer Therapy," (\$135,000/year). K. Sakamoto (P.I.)
- 7/04-7/05 Department of Defense, "Identification of small non-peptidic ligands that bind the SCF^{beta-TRCP} ubiquitin ligase to target the ER for ubiquitination and degradation (\$75,000). K. Sakamoto (P.I.)
- 7/05-5/07 Fulbright Fellowship/MEC (Spain) postdoctoral fellowship, "Targeting the Androgen Receptor for Ubiquitination and Degradation: A new strategy for Therapy in Prostate Cancer" (\$60,000), K. Sakamoto and R. Deshaies (Co-P.I.)
- 5/05 Boyer/Parvin Postdoctoral Fellow Award (\$5,000), awarded to Deepa Shankar, Ph.D., K. Sakamoto (P.I.)
- 7/05 Stone Research Award (\$1,000) award to undergraduate student Winston Wu, K. Sakamoto (P.I.)
- 7/05-6/07 Department of Defense postdoctoral fellowship, "Targeting the Androgen Receptor for Ubiquitination and Degradation: A New Strategy for Therapy in Prostate Cancer," (\$80,000), K. Sakamoto (P.I.)
- 10/06-9/07 Diamond Blackfan Anemia Foundation, "Developing a zebrafish model of Diamond Blackfan Anemia." \$25,000 (K. Sakamoto and S. Lin, P.I.)
- 10/05-9/09 NIH/NHLBI R01 (HL083077), "Molecular and Cellular Characterization of MPD." \$225,000/ year (K. Sakamoto, P.I.)
- 7/06-6/08 Department of Defense, "The Role of CREB in CML," \$45,800/year (K. Sakamoto, P.I.)

7/06-6/08 F32 HL085013 NRSA (NHLBI), "CREB and Hematopoietic Stem Cells " awarded to postdoctoral fellow Jerry Cheng, M.D. (K. Sakamoto, P.I.).

7/06-6/08 NCI T32 CA09056 Tumor Cell Biology Training Grant, "Studies in the Mechanisms of Targeted Therapy for Acute Myeloid Leukemia," for Al in K. Ikeda, M.D. (K. Sakamoto, P.I.).

10/06-9/09 Leukemia and Lymphoma Society Translational Research Grant, "Targeting Signaling Pathways in Pediatric AML." \$200,000/year (K. Sakamoto, P.I. and Ted Moore, co-P.I.).

1/07-12/12 T32 NIH/NHLBI Training Grant, "Training in Developmental Hematology." \$262,489/year (K. Sakamoto, P.I.).

1/08-12/08 Abbott Laboratories and Genentech, Inc. "RTKs in AML." \$50,000 (K. Sakamoto, P.I.).

10/08-9/09 Jonsson Comprehensive Cancer Center Fellowship award, "Targeting the Aggresome Pathway in ALL." \$30,000 (K. Sakamoto, P.I., Agustin Rodriguez-Gonzalez, fellow).

11/08-10/09 William Lawrence Foundation (\$40,000). Targeting the Aggresome pathway in Pediatric ALL. (K. Sakamoto, P.I.).

7/09-6/2010 St. Baldrick's Foundation (\$50,000). The Role of p53/deltaNp63 in Oncogenesis in Bone Marrow Failure Syndromes (K. Sakamoto and S. Lin, P.I.).

2009 NanoPediatrics Core Seed Grant (\$20,000). Identification of Molecular Targets of the CREB inhibitor XX-650-23 in Leukemia Cells. (K. Sakamoto, P.I.)

2010 Parents Against Leukemia (\$20,000). Genome sequence of pediatric ALL cells. (K. Sakamoto, P.I., Stan Nelson co-PI).

TRAINING FACULTY ON THE FOLLOWING TRAINING GRANTS (NIH T32 and K12 Programs)

Tumor Cell Biology
Tumor Immunology
Hematology
Vascular Biology
CHRCO
Medical Scientist Training Program (MSTP)
Gene Medicine
Stem Cell Research Institute
Training in Developmental Hematology (P.I.)

FACULTY MENTORSHIP

Faculty Mentor
Faculty Mentor
Faculty Mentor
Faculty Mentor

Ved Longhe, Assistant Professor In-Residence
Kek-Khee Loo, Assistant Professor In-Residence
Tumaini Coker, Assistant Clinical Professor
Valencia Walker, Assistant Clinical Professor

TRAINEES

1991-1993	Hu-Jung Julie Lee, undergraduate student
1992-1993	Elana Lehman, medical student
1993-present	Kathy Hwain Shin, undergraduate student, Work/study and Lab Assistant
1994-1995	Robert C. Mignacca, M.D., postdoctoral fellow
1994-1995	Stephen Phillips, undergraduate student, Student Research Project
1995	Allison Wong, medical student; Short Term Training Program; Recipient
of	Howard Hughes NIH Research Scholar Award, 1996-1997
1995	Ramona Rodriguez, medical student; Short Term Training Program, Centers of Excellence
1995-2000	Evelyn Kwon, graduate student
1996	Michael Mendoza, medical student, Short Term Training Program
Centers	of Excellence and FIRST/STAR Award recipient
1996-2002	Patricia Mora-Garcia (awarded Minority Supplement Award from NIH/NCI), Dept. Pathology and Laboratory Medicine
1996-2002	Michael Lin, graduate students (recipient of NIH/NCI Tumor Cell Biology Training Grant), Dept. Pathology and Laboratory Medicine
1997	Raymond Wang, medical student, Short Term Training Program
1995-1999	Wayne Chu, M.D., Pediatric Resident, Mattel Children's Hospital at UCLA, research elective (recipient of 1999 Merle Carson Lectureship, 1 st Prize Southwestern Pediatric Society, The Tenth Joseph St. Geme, Jr. Research Award for UCLA Pediatric Trainees)
1999-2000	Kristin Baird, M.D. Pediatric Resident, Mattel Children's Hospital at UCLA, research elective
2000-2007	Deepa Shankar, Ph.D., Postdoctoral fellow (NIH Tumor Cell Biology Postdoctoral fellowship, JCCC fellowship).
2001-2002	Heather Crans, graduate student (recipient of NIH Tumor Immunology Training Grant), Dept. Pathology and Laboratory Medicine
2001-2003	Athena Countouriotis, M.D., Pediatric Resident, Mattel Children's Hospital at UCLA, research elective (recipient of Resident Research Award, American Academy of Pediatrics)
2002-2007	Jerry Cheng, M.D., Pediatric Resident, Mattel Children's Hospital at UCLA (won SPR House Officer Award 2003, ASPHO/SPR meeting, Seattle, WA).
2002-2003	Tamara Greene, Medical Student, UCLA School of Medicine
2002-2003	Johnny Chang, M.D., Medical Oncology Fellow, Division of Hematology-Oncology, Department of Medicine, UCLA School of Medicine (recipient Of NIH Hematology Training Grant)
2003-2005	Noah Federman, M.D., Pediatric Resident, Mattel Children's Hospital, research elective
2003	Andy Liu, undergraduate student (Recipient of Undergraduate scholarship award for research performed in my laboratory)
2003	Ryan Stevenson, undergraduate student (now in medical school)

2004	Maricela Rodriguez, medical student
2005	Jenny Hernandez, Saul Priceman, Jose Cordero, Gloria Gonzales, Salemiz Sandoval
2005	Cid Sumolong, STTP, UCLA medical student
2005-2006	Winston Wu, undergraduate (recipient of John Stone Award for research performed in my laboratory)
2005-present	Salemiz Sandoval, graduate student (MBI)
2005-2007	Samuel Esparza, M.D., Pediatric Hematology-Oncology fellow, STAR/PhD graduate program
2005-2007	Jerry Cheng, M.D., Pediatric Hematology-Oncology fellow
2005-present	Tiffany Simms-Waldrip, M.D., postdoctoral fellow
2005	Katrin Rhodes, rotating ACCESS graduate student
2006	Sam Kaneko, first year UCLA medical student (STTP)
2006-2007	Kellie Lim, 4 th year medical student mentor, UCLA Medical Specialties College Program
2006-present	Jenny Hernandez, graduate student (Pathology)
2006-present	Alan Ikeda, M.D., Pediatric Hematology-Oncology fellow
2006-2008	Tara Lin, M.D., Adult Oncology, Postdoctoral fellow
2006	Andrew Goldsmith, ACCESS rotation student
2006-present	James Ch'ng, undergraduate student
2007-present	Chuck Gawad, Pediatric Resident, Mattel Children's Hospital
2007-present	Tiffany Chang, Pediatric Resident Mattel Children's Hospital
2007-present	AMA faculty mentoring program for medical students (Amanda Clauson and Supriya Bavisetty)
2007	Jo Chang, Pediatric Resident, Harbor-UCLA Medical Center
2007-present	Jessica Bushong, undergraduate student (recipient of CARE program award)
2008	Joan Zape, undergraduate student (Amgen Scholar Award), UC Riverside
2008	Derek Orejel (STTP), medical student, UC Riverside/UCLA
2008	Burcu Biterge, undergraduate student, Turkey
2008-present	Grace Masangkay, graduate student in Biochemistry
2008-present	Tiffany Simms-Waldrip, M.D., postdoctoral fellow
2008-2009	Kazunari Yamada, M.D., Ph.D., visiting professor
2008	Renee Butterworth, ACCESS graduate student (rotation)
2009	Diana Moughon, ACCESS graduate student (rotation)
2008-2009	Miranda Savani, UCLA undergraduate student
2009	Kazuo Okemoto, Ph.D., postdoctoral fellow
2010	Maya Budzinskaya, ACCESS graduate student (rotation)
2010	Eric Gschweng, ACCESS graduate student (rotation)

Ph.D. Thesis Committee for Graduate Students

Jason Christianson (P.I. A. Rajasekharan, Pathology) 9/10/01
 Robert Clipsham (P.I. Ed McCabe, M.D., Ph.D., Genetics) 7/01
 Jared Goldstine (P.I. Harry Vinters, Pathology) 3/31/04
 Jennifer Woo Tufts (P.I. Arnold Berk, Molecular Biology Institute) 3/07/06
 Jin Xu (P.I. Charles Sawyers, Molecular Biology Institute) 3/04
 Robert Signer (P.I. Ken Dorshkind, Pathology) 3/17/06
 Alexandria Young (P.I. Debora Farber, Ph.D., Ophthalmology) 4/26/06

Katrin Rhodes (P.I. Hanna Mikkola, Ph.D., MCDB)
Gustavo Gomez (P.I. Shuo Lin, Ph.D., MCDB)
Jeanette Grant (Steve Dubinett, M.D.)

LECTURES AND PRESENTATIONS

1. "Cytokine Signals and Cell Cycle Control During Myelopoiesis" Childhood Leukemia, Biological and Therapeutic Advances. April 17, 1998, Los Angeles, California.
2. Serine/Threonine Phosphorylation in Cytokine Signaling Workshop sponsored by the National Cancer Institute. March 30, 1999, Washington, D.C.
3. "Signal Transduction Pathways Activated by GM-CSF." October 29-30, 1999. ACS Professors Meeting, New York.
4. "Signal Transduction and Cell Cycle Control in Myeloid Cells" for Meet-the-Experts Breakfast, American Society of Hematology, December 5, 1999, New Orleans, LA.
5. CapCURE meeting, September 2000, Lake Tahoe. "Novel Approach to treat Prostate Cancer"
6. What SCF Ubiquitin Ligases Are and how they can be used to regulate cancer progression, JCCC, UCLA seminar, 4/01.
7. Bone marrow cells regenerate infarcted myocardium, Journal Club, 4/01
8. Acute Leukemia for Pediatric Residents at UCLA School of Medicine, 7/01
9. ITP, Olive View Grand Rounds, 8/01
10. Childhood Leukemia: causes and treatment. American Cancer Society, Los Angeles Chapter, 10/01
11. "The Role of SCF Ubiquitin Ligase in Human Disease: Implications for Therapy." Caltech Biolunch, March 6, 2002.
12. "Targeting Cancer-Promoting Proteins for Ubiquitination and Degradation" Signal Transduction Program Area Seminar, Jonsson Comprehensive Cancer Center, UCLA. August 1, 2003.
13. "Development of Approaches to Target Proteins for Ubiquitination and Degradation in Human Disease." Thesis Defense, Caltech. December 18, 2003.
14. "Role of CREB in Human Leukemias." Gene Medicine Seminar Series. Jan 26, 2004.
15. "Childhood Neutropenias." Pediatric Resident Noon conference. February 4, 2004.
16. "The Role of CREB in human leukemias", Gene Medicine Research Seminar, January 26th 2004.

17. "CREB and Acute Myeloid Leukemia," Leukemia Research Group Meeting, March 4, 2004.
18. "The Role of CREB in Leukemogenesis," Pediatric Research Seminar, May 20, 2004.
19. Meet the Professors lunch for UCLA ACCESS graduate students. October 6, 2004.
20. UCLA Training Program in Tumor Biology. Retreat for UCLA ACCESS graduate students. October 31, 2004.
21. "Hematology Jeopardy" Pediatric Noon Seminar, December 13, 2004.
21. "Transcriptional Regulators in Normal and Malignant Hematopoiesis," MBI Noon Seminar, November 30, 2004.
22. "Targeting Proteins for Ubiquitination and Degradation in Prostate Cancer" GU SPORE seminar, December 21, 2004.
23. "Writing your first NIH grant: an overview," Pediatric Research Seminar, April 7, 2005.
24. "Targeting the Ubiquitin-Proteasome System for Cancer Therapy." Minisymposium on Modulation of Protein Stability, AACR, Anaheim, CA, April 20, 2005.
25. "The Role of CREB in Myelopoiesis." Myeloid Workshop, Annapolis, MD, 2005
26. "The Use of RNA Interference to Study and Treat Human Disease." Organizer, Cell Biology Methods workshop, PAS/SPR meeting, Washington, D.C., 2005.
27. Young Investigators Workshop. American Society of Pediatric Hematology-Oncology meeting, Washington D.C. 2005.
29. "Update on Acute Leukemia: Where we've been and where we are today." Pediatric Grand Rounds, Children's Hospital of Los Angeles. August 19, 2005.
30. "Acute Myeloid Leukemia," Pediatric Resident Rounds, September 21, 2005.
30. "Grants Writing Workshop," ACCESS graduate students, September 26, 2005.
31. "COG Spring Meeting Report on Acute Leukemia." Tuesday 3pm Division Conference, March 28, 2006.
32. "Successes and Challenges of Childhood Cancer: Leukemia as a Model." Life after Childhood Cancer, March 29, UCLA symposium sponsored by the Leukemia and Lymphoma Society of America.
33. "The Cancer Problem." M294 Basic Concepts in Oncology Course, April 3, 2006.
34. "Update on Childhood Leukemia." Pediatric Grand Rounds, Charles R. Drew University of Medicine and Science, April 4, 2006.

35. "Choosing a Career in Basic Science Research." Young Investigator Workshop (organizer). ASPHO/SPR meeting. April 30, 2006.
36. "RNA interference and Stem Cells," New Approaches in Stem Cell Technologies Workshop, SPR meeting, San Francisco, California. April 29, 2006.
37. "Leukemia." M294 Basic Concepts in Oncology Course, May 10, 2006.
38. "Update on Childhood Leukemias." Olive View Grand Rounds, May 17, 2006.
39. "Leukemia" Pediatric Resident Noon Lecture, June 5, 2006.
40. "State of Art lecture on AML/Myelodysplastic Syndromes" for fellows, Division Conference, Tuesday July 18, 2006.
41. "Preparation of the RRC Site Visit." Division Conference, August 29, 2006.
42. "Molecular and Cellular Characterization of MPD: The Role of CREB in Myelopoiesis." NIH/NHLBI grantees meeting on MPD and MDS, November 9, 2006.
43. "How to write your first NIH grant: an overview." Pediatric Fellows Noon Seminar, February 29, 2007.
44. "Promotions; Rising up the Academic Ladder." Young Investigator's Workshop, ASPHO meeting, May 2007.
45. "Childhood Leukemia." Harbor-UCLA Pediatric Grand Rounds, May 24, 2007.
46. "Introduction to Cancer." Pathology M294 Basic Concepts in Oncology, April 2, 2007.
47. "Acute and Chronic Leukemia." Pathology M294 Basic Concepts in Oncology, June, 2007.
48. "Update on Childhood Leukemia." Cedars-Sinai Hematology-Oncology Grand Rounds, August 14, 2007.
48. "Role of CREB in normal and neoplastic myelopoiesis." Hematopoiesis Group seminar series/Journal Club, October 19, 2007.
49. "New therapies for acute leukemia." Leukemia and Lymphoma Society of America fundraiser, Parents Against Leukemia, Woodland Hills, October 27, 2007.
50. "Molecular Characterization of CREB in MPD." NHLBI Grantees meeting, November 6, 2007.
51. "Molecular pathogenesis and Targeted therapies in leukemia," Pediatric Hematology-Oncology, NCI, November 8, 2007.

52. "CREB downregulation in normal and neoplastic hematopoietic cells." Invited speaker, Gene Therapy Symposium, Nappa Valley, November 15, 2007.
53. ASH meeting 2000 report. Tuesday 3pm conference. December 18, 2007.
54. PCRF symposium: 25 years of Cancer Research, "Molecular Mechanisms of AML and targeted therapies." Invited speaker, Anaheim, California. January 11, 2008.
55. University of Wisconsin Frontiers in Pharmacology, "Molecular Mechanisms of Leukemogenesis and Targeted Therapies." Invited speaker, March 25, 2008. Madison, Wisconsin.
56. AACR Roundtable Session on "Careers in Clinical and Translational Cancer Research." San Diego, April 12, 2008.
57. AACR Session Chair for Minisymposium on "Gene Regulation in Cancer," AACR meeting. San Diego, April 14, 2008.
58. "Acute Leukemia and Targeted Therapies." Pathology M294 Basic Concepts in Oncology, May 5, 2008.
59. "Molecular Mechanisms of Leukemogenesis and Targeted Therapies." Cincinnati Children's Hospital, May 12, 2008.
60. "How to write your first NIH grant." Young Investigator's Workshop, American Society of Pediatric Hematology-Oncology annual meeting, Cincinnati Ohio. May 15, 2008.
61. Sakamoto KM and Joanne Hilden. "Ethics and Writing." Young Investigator's Workshop, American Society of Pediatric Hematology-Oncology annual meeting, Cincinnati Ohio. May 15, 2008.
62. Sakamoto KM and Jeff Lipton. "Translational Research: how not to fall between the bench and the bedside". American Society of Pediatric Hematology-Oncology annual meeting, Cincinnati Ohio. May 17, 2008.
63. "Childhood Leukemia." Pediatric Resident noon conference. UCLA, June 25, 2008.
64. First year Fellow Orientation, Mattel Children's Hospital UCLA, July 2, 2008.
64. "Introduction to Professionalism," Professionalism Workshop for Pediatric Hematology/Oncology fellows. July 30, 2008.
65. "Neutropenia". Division of Pediatric Hematology-Oncology Lecture, August 5, 2008.
66. "Mechanisms of Leukemogenesis and Targeted Therapies". City of Hope seminar, September 17, 2008.

67. "Protacs: Targeting Proteins for Ubiquitination and Degradation." UCLA Nanopediatrics symposium, October 17, 2008.
69. "Targeting Proteins for ubiquitination and degradation for cancer therapy." AACR-NCI-EORTC meeting, Geneva, Switzerland, October 22, 2008.
70. "Protacs: Targeting proteins for ubiquitination and degradation to treat cancer." CNS new members seminar, October 30, 2008.
72. "Molecular Regulation of MPD." NIH MPD grantees meeting, Bethesda, Maryland. November 14, 2008.
73. "The Role of GM-CSF and CREB in myeloid proliferation and survival" Speaker and Chair of Myeloid Biology Subcommittee Session. American Society of Hematology Meeting, San Francisco, CA. December 2008
74. "Myelodysplastic disease in children" Simi Valley Hospital, January 22, 2009.
75. "Signaling pathways downstream of RPS19 and RPL11 deficiency in zebrafish and hematopoietic cells." DBA ICC Meeting, New York City, NY. March 14, 2009.
76. "Mechanisms of leukemogenesis and targeted therapies," Fernbach Distinguished Lectureship. Texas Children's Hospital, Houston Texas. April 2, 2009.
77. "Alternative models of DBA." Session Chair, Ribosome-based diseases. American Society of Pediatric Hematology/Oncology. San Diego, California. April 26, 2009.
78. "CREB regulates normal hematopoiesis and contributes to development of AML." NIH Myeloid Stem Cell meeting, Annapolis, Maryland. May 10, 2009.
79. "Ubiquitin and Ubiquitin-like Modifiers for Cancer Therapy." American Society of Clinical Oncology. Orlando, Florida. June 2, 2009.
80. "Childhood Leukemia." Pediatric Resident's noon lecture. Mattel Children's Hospital UCLA. June 10, 2009.
81. "PNH." Faculty didactic lecture, Division Conference. September 29, Mattel Children's Hospital UCLA.
82. "Pediatric Hematology/Oncology." UCLA Pre-Med Peer Association, November 12, 2009.

PUBLICATION/BIBLIOGRAPHY

PEER-REVIEWED

1. Nagahashi, G and Hiraike (Sakamoto) KM. Effect of centrifugation time on sedimentation of plant organelles. Plant Physiol 69:546-548, 1982.

2. Yamamoto J, Yap J, Hatakeyama J, Hatanaka H, Hiraike (Sakamoto) K, Wong L: Treating Asian Americans in Los Angeles. Psychiatry 8:411-416, 1985.
3. Sakamoto KM, Bardeleben C, Yates KE, Raines MA, Golde DW, Gasson JC: 5' upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8. Oncogene 6:867-871, 1991.
4. Sakamoto KM, Nimer SD, Rosenblatt JD, Gasson JC: HTLV-I and HTLV-II tax *trans*-activate the human EGR-1 promoter through different *cis*-acting sequences. Oncogene 7:1125-1130, 1992.
5. Sakamoto-K, Erdreich Epstein A, deClerck Y, Coates T: Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am J P & Hemat Oncol 14:348-351, 1992.
6. Sakamoto KM, Fraser JK, Lee H-J J, Lehman E, Gasson JC: GM-CSF and IL-3 signaling pathways converge on the CREB-binding site in the human EGR-1 promoter. Mol Cell Biol 14:5920-5928, 1994.
7. Lee H-J J, Mignacca RM, and KM Sakamoto. Transcriptional activation of *egr-1* by Granulocyte-Macrophage Colony-Stimulating Factor but not Interleukin-3 requires phosphorylation of CREB on Serine 133. J. Biol. Chem., 270: 15979-15983, 1995.
8. Wong A and KM Sakamoto. GM-CSF-Induces the Transcriptional Activation of *Egr-1* Through a Protein Kinase A-Independent Signaling Pathway. J. Biol. Chem. 270: 30271-30273, 1995.
9. Horie M, Sakamoto KM, Broxmeyer HC. Regulation of *egr-1* gene expression by retinoic acid in a human growth factor-dependent cell line. Int J Hematology, 63: 303-309, 1996.
10. Mignacca RC, Lee H-J J, and KM Sakamoto. Mechanism of Transcriptional Activation of the Immediate Early Gene *Egr-1* in response to PLXY321. Blood, 88: 848-854, 1996.
11. Kao CT, Lin M, O'Shea-Greenfield A, Weinstein J, and KM Sakamoto. p55Cdc Overexpression Inhibits Granulocyte Differentiation Through an Apoptotic Pathway. Oncogene, 13:1221-1229, 1996.
12. Kwon EM and KM Sakamoto. Molecular Biology of Myeloid Growth Factors. J. Inv Med, 44: (8) 442-445 October, 1996.
13. Watanabe S, Kubota H, Sakamoto KM, and K Arai. Characterization of *cis*-acting sequences and *trans*-acting signals regulating early growth response gene 1 (*egr-1*) promoter through granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. Blood, 89:1197-1206, 1997.
14. Lin M, Mendoza M, Kane L, Weinstein J, and KM Sakamoto. Analysis of Cell Death in Myeloid Cells Inducibly Expressing the Cell Cycle Protein p55Cdc. Experimental Hematology 26, 1000-1007, 1998.

15. Weinstein J, Krumm J, Karim J, Geschwind D, and Nelson SF and KM Sakamoto. Genomic Structure, 5'Flanking Enhancer sequence, and chromosomal assignment of cell cycle gene, p55Cdc. Molecular Genetics and Metabolism, 64: 52-57, 1998.
16. Rolli M, Kotlyarov A, Sakamoto KM, Gaestel M, and Neininger A. Stress-induced Stimulation of Early Growth Response Gene-1 by p38/Stress-activated Protein Kinase 2 is Mediated by a cAMP-responsive Promoter Element in a MAPKAP Kinase 2-independent Manner. J Biol Chem, 274: 19559-19564, 1999.
17. Chu Y-W, Wang R, Schmid I and Sakamoto KM. Analysis of Green Fluorescent Protein with Flow Cytometry in Leukemic Cells. Cytometry, 333-339, 1999.
18. Aicher WK, Sakamoto KM, Hack A, and Eibel H. Analysis of functional elements in the human Egr-1 gene promoter. Rheumatology International, 18: 207-214, 1999.
19. Kwon EM, Raines MA and KM Sakamoto. GM-CSF Induces CREB Phosphorylation Through Activation of pp90Rsk. Blood, 95: 2552-2558, 2000.
20. Mora-Garcia PM and KM Sakamoto. Potential Role of SRF and Fli-1 in G-CSF-induced Egr-1 Gene Expression. J Biol Chem, 275: 22418-22426, 2000.
21. Wu H, Lan Z, Li W, Wu S, Weinstein J, Sakamoto KM, Dai W. BUBR1 Interacts with and phosphorylates p55Cdc/hCdc20 in a Spindle Checkpoint-dependent manner. Oncogene, 19: 4557-4562, 2000.
22. Wong A, KM Sakamoto, and EE Johnson. Differentiating Osteomyelitis and Bone infarctions in sickle cell patients. Ped Em Care, 17:60-66, 2001.
23. Lin M and KM Sakamoto. p55Cdc/Cdc20 Overexpression Promotes Early G1/S Transition in Myeloid Cells. Stem Cells 19: 205-211, 2001.
24. Shou W, Sakamoto KM, Keener J, Morimoto KW, Hoppe GJ, Azzam R, Traverso EJ, Feldman RFR, DeModena J, Charbonneau H, Moazed D, Nomura M and RJ Deshaies. RENT complex stimulates RNA Pol I transcription and regulates nucleolar structure independent of controlling mitotic exit. Mol Cell, 8: 45-55, 2001.
25. Sakamoto KM, Crews CC, Kim KB, Kumagai A, Mercurio F, and RJ Deshaies. Proac: A Chimeric Molecule that targets Proteins to the SCF for Ubiquitination and Degradation. Proc Natl Acad Sci USA, 98: 8554-8559, 2001.
26. Gubina E, Luo X, Kwon EM, Sakamoto KM, Shi YF and RA Mufson. β c Receptor Cytokine Stimulation of CREB Transcription Factor Phosphorylation by Protein Kinase C α A Novel Cytokine Signal Transduction Cascade. J Immunol 167: 4303-4310, 2000.
27. Xu Z, Cziarski R, Wang Q, Swartz K, KM Sakamoto, and D Gupta. Bacterial peptidoglycan-induced TNF- α transcription is mediated through the transcription factors Egr-1, Elk-1, and NF-kB. J Immunol, 167: 6972-6985, 2001.

28. Crans H, Landaw E, Bhatia S, Sandusky G, and KM Sakamoto. CREB Overexpression in Acute Leukemia. Blood, 99: 2617-2619, 2002.
30. Mendoza MJ, Wang CX, Lin M, Braun J, and KM Sakamoto. Fizzy-related RNA expression patterns in mammalian development and cell lines. Mol Genet Metab, 76:3663-3666, 2002.
29. Mora-Garcia P, Pan R, and KM Sakamoto. G-CSF Regulation of SRE-binding proteins in myeloid leukemia cells. Leukemia, 16: 2332-2333, 2002
31. Lin M, Chang JK, and KM Sakamoto. Regulation of the Cell-cycle by p53 in myeloid cells. Exp Mol Path, 74: 123-8, 2003.
32. Mora-Garcia P, Cheng J, Crans-Vargas H, and KM Sakamoto. The role of SRE-binding proteins and CREB in Myelopoiesis. Stem Cells, 21:123-130, 2003.
33. Hsu H, Rainov NG, Quinones A, Eling DJ, Sakamoto KM, and MA Spears. Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter. Anticancer Res 23: 2723-2728, 2003.
34. Countouriotis A, Landaw EM, Naiem F, Moore TB, and KM Sakamoto. Comparison of Bone Marrow Aspirates and Biopsies in Pediatric Patients with Acute Lymphoblastic Leukemia at days 7 and 14 of Induction Therapy. Leuk Lymphoma, 45:745-747, 2004.
35. Sakamoto KM, Kim KB, Verma R, Ransick A, Stein B, and RJ Deshaies. Development of Prodrugs to Target Cancer-Promoting Proteins for Ubiquitination and Degradation. Mol Cell Proteomics, 12:1350-1358, 2003.
36. Wang Q, Liu T, Fang Y, Xie S, Huang X, Mahmood R, Ramaswamy G, Sakamoto KM, Darynkiewicz Z, Xu M, and W Dai. BUBR1-deficiency results in Abnormal Megakaryopoiesis. Blood, 103: 1278-1285, 2004.
37. Schneekloth JS, Fonseca F, Koldobskiy M, Mandal A, Deshaies RJ, Sakamoto KM, CM Crews. Chemical Genetic Control of Protein Levels: Selective *in vivo* Targeted Degradation. J Amer Chem Soc, 126(12); 3748-3754, 2004.
38. Verma R, Peters NR, Tochtrop G, Sakamoto KM, D'Onofrio, Varada R, Fushman D, Deshaies RJ, and RW King. Ubistatins, a Novel Class of Small Molecules that inhibit Ubiquitin-Dependent Proteolysis by Binding to the Ubiquitin Chain. Science, 306:117-120, 2004.
39. Cheng JC, Esparza SD, Knez VM, Sakamoto KM, and TBM Moore. Severe Lactic Acidosis in a 14-year old female with Metastatic Undifferentiated Carcinoma of Unknown Primary. Am J Pediatr Hem Onc, 26:780-782, 2004.
40. Mora-Garcia P, Wei J, and KM Sakamoto. G-CSF Induces Stabilization of Ets Protein Fli-1 During Myeloid Cell Development. Pediatr Res, 1:63-66, 2005.

41. Shankar D, Cheng J, Kinjo K, Wang J, Federman N, Gill A, Rao N, Moore TB, Landaw EM and KM Sakamoto. The role of CREB as a proto-oncogene in Hematopoiesis and in Acute Myeloid Leukemia. Cancer Cell, 7:351-362, 2005.
42. Shankar D, Cheng JC, and KM Sakamoto. The Role of Cyclic AMP Response Element Binding Protein in Human Leukemias. Cancer, 104:1819-1824, 2005.
43. Kinjo K, Sandoval S, KM Sakamoto and DB Shankar. CREB as a Proto-oncogene in Hematopoiesis. Cell Cycle, 4: 1134-1135, 2005.
44. Sakamoto KM. Chimeric Molecules to Target Proteins for Ubiquitination and Degradation. Methods in Enzymology (Ubiquitin and Proteasome System), 299C: 833-837, 2005.
45. Sakamoto KM. Academic Training Pathways in Pediatric Hematology-Oncology. Pediatric Blood and Cancer, Nov 7, 2005.
46. Priceman SJ, Kirzner JD, Nary LJ, Morris D, Shankar DB, Sakamoto KM, and RD Medh. Calcium-Dependent Up Regulation of E4BP4 Expression Correlates With Glucocorticoid-Evoked Apoptosis of Human Leukemic CEM Cells. BBRC, 344(2):491-9. Epub 2006 Apr 5.
47. Shankar DB, Li J, Tapang P, McCall JO, Pease LJ, Dai Y, Wei RQ, Albert DH, Hartaedi K, Michaelides M, Davidsen SK, Priceman S, Chang J, Shah N, Moore TB, Sakamoto KM, and KB Glaser. ABT-869 a Multi-Targeted Receptor Tyrosine Kinase Inhibitor: Inhibition of FLT3 Phosphorylation and Signaling in AML, Blood, 109: 3400-3408, 2007 (*co-senior author).
48. Cheng JC, Horwitz EM,.... Kornblum H, Malik P, KM Sakamoto. New Technologies in Stem Cell Research. Meeting report from Society for Pediatric Research meeting (April 2006), Stem Cells, *in press*.
49. Cheng JC, Esparza SD, Sandoval S, Shankar DB, and KM Sakamoto. The potential role of CREB as a prognostic marker in leukemia. Future Oncology, 3:475-80, 2007.
50. Yang Z, Jiang H, Zhao F, Shankar DB, Sakamoto KM, Zhang MQ, and S Lin. A highly conserved distal regulatory element controls hematopoietic expression of *GATA-2*. BMC Developmental Biology, 7:97, 2007.
51. Lin TL, Fu C, and KM Sakamoto. Cancer Stem Cells: the root of the problem. Peds Res, 62:239, 2007
52. Esparza S, Chang J, Shankar D, Zhang B, Nelson S, and KM Sakamoto. CREB regulates Meis1 Expression in Normal and Malignant Hematopoietic Cells, Leukemia, Sept 6; Epub, 2007.
53. Cheng JC, Kinjo K, Wu WS, Schmid I, Shankar DB, Stripecke R, Kasahara N, Bhatia R, Landaw EM, Nelson S, Pelligrini M, and KM Sakamoto. CREB is a critical regulator of normal hematopoiesis and leukemogenesis, Blood, 111:1182-1192, 2008.

54. Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, and KM Sakamoto. Role of the Aggresome Pathway in Cancer: Targeting HDAC6 for therapy. Cancer Research, 68:2557-2560, 2008.
55. Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Fu C, and KM Sakamoto. Targeting the Aggresome Pathway in Hematologic Malignancies. Mol Gen Metab, 94:281-286; 2008.
56. Rajasekaran SA, Christiansen JJ, Schmid I, Oshima E, Sakamoto KM, Weinstein J, Rao NP, Rajasekaran AK. Prostate specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther, 7:2142-51, 2008.
57. Danilova N, Sakamoto KM, and S Lin. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood, Epub May 30, 112(13):5228-37, 2008.
58. Pellegrini M, Cheng JC, Voutila J, Judelson D, Taylor JA, Nelson SF, and KM Sakamoto. Expression Profile of CREB knockdown in Myeloid Leukemia Cells. BMC Cancer, 18:8264, 2008 [Epub].
59. Rodriguez-Gonzalez A, Cyrus K, Salcius M, Kim KB, Crews CM, Deshaies RJ, and KM Sakamoto. Targeting Steroid Hormone Receptors for Ubiquitination and Degradation in Breast and Prostate Cancer, Oncogene, 27:7201-11, 2008.
60. Danilova N, Sakamoto KM, and S Lin. Role of p53 Family in Birth Defects: Lessons from Zebrafish. Birth Defects Research (Part C), 84:215-27, 2008.
61. Danilova, N., KM Sakamoto, and S. Lin, p53 family in development, Mech Development, 125:919-31, 2008.
62. Sandoval S, Pigazzi M, and KM Sakamoto. CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. Adv Hematol, *in press*.
63. Ikeda AI, Judelson D, Federman N, Glaser K, Landaw EM, Denny CT, and KM Sakamoto. ABT-869 Suppresses Proliferation of Ewing Sarcoma cells by Inhibiting PDGFR β and c-Kit-dependent Pathways. Molecular Cancer Therapeutics, *in press*.
64. Sakamoto, K.M. Protacs for Treatment of Cancer. Annual Review Issue of Pediatrics Research on Nanopediatrics, *in press*.

REVIEWS

1. Sakamoto KM, Golde DW, Gasson JC: The biology and clinical applications of granulocyte-macrophage colony-stimulating factor. J Pediatr 118:S17-S20, 1991.
2. Sakamoto KM, Gasson JC: Clinical applications of human granulocyte-macrophage colony-stimulating factor. Int J Cell Cloning 9:531-541, 1991.

3. Sakamoto KM, Mignacca RC, Gasson JC: Signal transduction by granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors. Receptors and Channels, 2: 175-181, 1994.
4. Mora-Garcia P and KM Sakamoto. Signal Transduction and Human Disease. Molecular Genetics and Metabolism, 66, 143-171, 1999.
5. Chu Y-W, Korb J and KM Sakamoto. Immune Thrombocytopenia Purpura. Pediatrics In Review, 21: 95-104, 2000.
6. Sakamoto, KM. Genetic and Functional Consequences of Cell Cycle Alteration in Cancer. AACR Special conference. 20-24 October 1999, San Diego, CA, USA. Idrugs 2000 3: 36-40.
7. Vu PK and KM Sakamoto. Ubiquitin-Mediated Proteolysis and Human Disease, Mol Gen Metab, 71: 261-266, 2000.
8. Crans H and KM Sakamoto. Transcription factors and Translocations in lymphoid and myeloid leukemia. Leukemia, 15: 313-331, 2001.
9. Shankar D and KM Sakamoto. Cell cycle control in normal and malignant hematopoiesis. Recent Advances in Blood Research, 1:47-71, 2001.
10. Countouriotis A, Moore TB, and KM Sakamoto. Molecular targeting in the treatment of hematologic malignancies. Stem Cells, 20:215-229, 2002.
11. Sakamoto KM. Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. Mol Genet Metab 77:44-56, 2002.
12. Sakamoto KM. Targeting Ubiquitinylation for Drug Discovery. Meeting review, Idrugs 5: 779-781, 2002.
13. Cheng J, Moore TB, and KM Sakamoto. RNA interference and Human Disease. Mol Genet Metab, 80: 121-128, 2003.
14. Shankar D and KM Sakamoto. The Role of Cyclic-AMP Binding Protein (CREB) in leukemia cell proliferation and acute leukemias. Leuk Lymphoma, 45:265-70, 2004.
15. Sakamoto KM. Knocking Down Human Disease: Potential uses of RNAi in Research and Gene Therapy. Pediatr Res, 55:912-913, 2004.
16. Cheng JC and KM Sakamoto. The Emerging Role of RNA Interference in the Design of Novel Therapeutics in Oncology (invited review), Cell Cycle, 3: 1398-1401, 2004.
17. Sakamoto KM. A Pediatric Approach to Classification of MDS. Highlights of the American Society of Pediatric Hematology-Oncology 17th Annual Meeting, May 2004. Medscape from WebMD.

18. **Sakamoto KM.** Understanding the Pathophysiology of Marrow Failure in MDS. Highlights of the American Society of Pediatric Hematology-Oncology 17th Annual Meeting, May 2004. Medscape from WebMD.
19. **Sakamoto KM.** Clinical Aspects of Childhood MDS. Highlights of the American Society of Pediatric Hematology-Oncology 17th Annual Meeting, May 2004. Medscape from WebMD.
20. **Esparza SD and KM Sakamoto.** Topics in Pediatric Leukemia-Acute Lymphoblastic Leukemia. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.
21. **Casillas J and KM Sakamoto.** Topics in Pediatric Leukemia-Acute Lymphoblastic Leukemia and Late Effects in Long-Term Survivors. MedGenMed Hematology-Oncology published online on Medscape from WebMD, 2005.
22. **Lasky J and KM Sakamoto.** Topics in Pediatric Leukemia-Myelodysplastic and Myeloproliferative Disorders of Childhood. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.
23. **Cheng JC and KM Sakamoto.** Topics in Pediatric Leukemia-Acute Myeloid Leukemia. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.
24. **Moore TB and KM Sakamoto.** Topics in Pediatric Leukemia-Hematopoietic Stem Cell Transplantation. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.
25. **Federman N and KM Sakamoto.** Topics in Pediatric Leukemia-Fanconi's Anemia: New Insights. MedGenMed Hematology-Oncology, published online on Medscape from WebMD, 2005.
26. **Federman N and KM Sakamoto.** The Genetic Basis of Bone Marrow Failure Syndromes in Children, Mol Gen Metab, 76:3663-366, 2005.
27. **Parcells B, Ikeda AK, Simms-Waldrip T, Shankar DB, Moore TB, and KM Sakamoto.** The Role of FLT3 in Normal Hematopoiesis and AML, Stem Cells, 24(5):1174-84, 2006.
28. **Ikeda AK, Simms-Waldrip T, Shankar DB, Watanabe M, Tamanoi F, Moore TB, and KM Sakamoto.** Molecular Targets and the Treatment of Acute Myeloid Leukemia, Mol Gen Metab, 88:216-224, 2006.
29. **Morimoto K, Lin S, and KM Sakamoto.** The Functions of RPS19 and Their Relationship to Diamond-Blackfan Anemia: A Review. Mol Gen Metab, Dec 16, 2006 [epub].
30. **Fu C and KM Sakamoto.** Peg-Asparaginase (Invited Review). Expert Opinion on Pharmacotherapy, 8: 1977-1984, 2007.
31. **Gawad C, Fu C, and KM Sakamoto.** Emerging Immunotherapeutic Strategies to Treat Pediatric AML. Touch Briefings in US Pediatrics Review, 2007.

32. Hernandez J, Yamada K, Ikeda A, and KM Sakamoto. The Role of FLT3 Inhibitors in AML. *Submitted to Molecular Biosystems*.

Xiao X, Li B, Mitton B, Ikeda A, and KM Sakamoto. Targeting CREB for Cancer Therapy: Friend or Foe? *Manuscript submitted*.

BOOK CHAPTERS

1. Gasson JC, Baldwin GC, Sakamoto KM, DiPersio JF: The biology of human granulocyte-macrophage colony-stimulating factor (GM-CSF). In The Biology of Hematopoiesis, Dai L, N. Cronkite EP, McCaffrey R, Shadduck RK (eds). John Wiley & Sons, New York, 1990, pp. 375-384.

2. Schmid I and KM Sakamoto, Analysis of DNA Content and Green Fluorescent Protein Expression. Current Protocols in Flow Cytometry, 7.16.1-7.16.10, 2001.

3. Baird K and KM Sakamoto. Polycythemia. Manuscript (online) for Textbook in Pediatrics, emedicine.com, 2002.

4. Hagey A and KM Sakamoto. White Cell Disorders. Manuscript (online) for Textbook in Pediatrics, emedicine.com, 2001.

5. Buchbinder D and KM Sakamoto. White Cell Disorders (updated). Manuscript (online) for Textbook in Pediatrics, emedicine.com, 2005.

6. Baird K and KM Sakamoto. Polycythemia (updated). Manuscript (online) for Textbook in Pediatrics, emedicine.com, 2005.

7. Rodriguez-Gonzales A and KM Sakamoto. Proteolysis Targeting Chimeric molecules Recruiting Cancer-Causing Proteins for Ubiquitination and Degradation. Modulation of Protein Stability in Cancer Therapy (Eds. KM. Sakamoto and E Rubin), *in press*.

LETTERS AND COMMENTARIES

1. Sakamoto KM and K Dipple. Becoming a Pediatric Physician-Scientist: A Woman's Perspective. *Acad Med*, *in press*.

2. Sakamoto K. Balancing work and life: Interview with Kathleen Sakamoto. *Stem Cells* 27(9): 2053-5, 2009.

3. Vaiselbuh S, Sakamoto KM, and JM Lipton. Translational Medicine: How not to fall between the bench and the bedside, *submitted*.

ABSTRACTS

1. Sakamoto K, Raines MB, Bardeleben C, Gasson JC: GM-CSF and TPA induce a subset of primary response TIS genes in both proliferating and terminally differentiated myeloid cells. American Society of Hematology; November, 1989. Blood 74(7):73a.

2. Sakamoto K, Gasson JC: GM-CSF-responsive sequences upstream of the primary response gene, EGR-1/TIS8, in factor-dependent human myeloid leukemia cell lines. Blood 76(1):117a, 1990.
3. Sakamoto K, Gasson JC: GM-CSF-responsive sequences upstream of the primary response gene, EGR-1/TIS8, in factor-dependent human myeloid leukemia cell lines. Presented at Keystone Symposia on Molecular & Cellular Biology, "Cytokines and Their Receptors". J Cell Biochem 15F:P556, 1991.^
4. Sakamoto K, Rosenblatt J, Gasson JC: *Trans*-activation of the human EGR-1 promoter by the HTLV-I and -II Tax proteins in T-cell lines. Blood 78:266a, 1991.^
5. Gilliland DG, Perrin S, Sakamoto KM, Bunn HF: Analysis of EGR-1 and other relevant genes in patients with 5q- syndrome. Blood 78:333a, 1991.
6. Sakamoto KM, Lee J, Gasson JC: GM-CSF-responsive sequences upstream of the primary response gene, EGR-1/TIS8, in a human factor-dependent myeloid leukemia cell line. J Cell Biochem 16C:M234, 1992.^
7. Sakamoto KM, Lee JH, Gasson JC: GM-CSF and IL-3 induce EGR-1 transcriptional activation through both overlapping and distinct upstream regulatory sequences. Leukemia 6:1093, 1992.
8. Sakamoto KM, Lee JH-J, Gasson JC: GM-CSF and IL-3 mediate signal transduction through both overlapping and distinct upstream regulatory sequences in the human EGR-1 promoter. Blood 80:974, 1992.^
9. Sakamoto KM, Lee JH-J, Gasson JC: GM-CSF and IL-3 activate human early response gene (EGR-1) transcription through both overlapping and distinct upstream regulatory sequences. J Cell Biochem 17A:B974, 1993.
10. Sakamoto KM, Lee JH-J, Lehman ES, Gasson JC: GM-CSF and IL-3 induce early response gene expression through a novel transcription factor binding site. Blood 82:437, 1993.^
11. Horie M, Sakamoto KM, Aronica S, Broxmeyer HE: Regulation of EGR-1 gene transcription by retinoic acid in a human factor-dependent cell line. Presented at the International Society of Experimental Hematology, 22:721; Minneapolis, MN; August 1994.
12. Sakamoto KM, Lee H-J, Lehman ES, and Gasson JC: GM-CSF and IL-3 signal transduction in myeloid leukemic cells. Oral presentation and acceptance of the Young Investigator Award in Oncology, The American Society of Pediatric Hematology-Oncology, Chicago, IL; October 1994.^
13. Sakamoto KM, Lee H-J, Lehman ES, and Gasson JC: GM-CSF and IL-3 Signal Transduction Pathways Converge on the Egr-1 and CREB-binding Sites in the Human egr-1 promoter. Presented to the American Association for Cancer Research meeting on

Transcriptional Regulation of Cell Proliferation and Differentiation, Chatham, MA; October 1994.

14. Mignacca RC and Sakamoto KM. Transcriptional Regulation of the Human *egr-1* gene by PIXY321 in a factor-dependent myeloid leukemic cell line. Presented to the American Association for Cancer Research meeting on Transcriptional Regulation of Cell Proliferation and Differentiation, Chatham, MA; October 1994.

15. Kubota H, Watanabe S, Sakamoto K and Arai K. Transcriptional activation of early growth response gene-1 (EGR-1) by human granulocyte-macrophage colony-stimulating factor. Japanese Immunological Meetings, JAPAN; November 1994.

16. Lee H-J, Gasson JC and Sakamoto KM. GM-CSF and IL-3 Activate Signaling Pathways through phosphorylation of CREB in myeloid leukemic cells. *Blood* 84 (10): 15a, 1994. Abstract accepted for poster presentation.

17. Mignacca RC and Sakamoto KM. PIXY321 responsive sequences of the human *egr-1* promoter mediating proliferation in a factor-dependent myeloid leukemic cell line. *Blood* 84 (10): 572a, 1994.

18. Mignacca RC and Sakamoto KM. Transcriptional Regulation of the Human *egr-1* gene by PIXY321 in a factor-dependent myeloid leukemic cell line. *J. Cell. Biochem. Abstract Supp* 19A: A1-335, 1995. Keystone Symposia on Oncogenes, Keystone, CO; January 1995.

19. Raitano AB, Mignacca RC, Sakamoto KM, and Sawyers CL. Differential effects of the leukemogenic fusion proteins *v-abl* and *bcr-abl* in activation of *myc* and *ras* responsive promoter elements. *J. Cell. Biochem. Abstract Supp* 19A: A1-347. Presented at Keystone Symposia on Oncogenes, Keystone, CO; January 1995.

20. H-J Lee, JC Gasson, and KM Sakamoto. Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3 Activate Signaling Pathways Through Phosphorylation of CREB in Myeloid Leukemic Cells. Western Society for Pediatric Research, Carmel, CA; February 1995.

21. A. O'Shea-Greenfield, J. Weinstein, and K.M. Sakamoto. Inhibition of Granulocyte Differentiation by a Novel Cell Cycle Protein p55CDC. Abstract accepted for poster presentation, American Society of Hematology Meeting, December 1995.

22. A. O'Shea-Greenfield, J. Weinstein, and KM Sakamoto. Cell Cycle Regulation by a Novel Protein p55CDC. Abstract accepted for oral presentation, American Society of Hematology Meeting, December 1995.

23. A. Wong and KM Sakamoto. GM-CSF Induces the Transcriptional Activation of *Egr-1* Through a Protein Kinase A-Independent Signaling Pathway. Abstract accepted for poster presentation, American Society of Hematology Meeting, December 1995.

24. KM Sakamoto. Molecular Biology of Myeloid Growth Factors, presented as the Rosalind Young Investigator Award at the 1996 Western Society for Pediatric Research meeting, Carmel, February 15, 1996.

24. A. Wong and **KM Sakamoto**. GM-CSF induces transcriptional activation of *egr-1* promoter through a protein kinase A-independent signaling pathway. Oral presentation by A. Wong at the Western Society for Pediatric Research, Carmel, February 16, 1996.^
25. Kao CT, O'Shea-Greenfield A, Weinstein J, **Sakamoto KM**. Overexpression of p53 Cdc accelerates apoptosis in myeloid cells. Oral presentation at the International Society of Hematology August 1996, Singapore.^
26. Lin M, Mendoza M, Weinstein J, **Sakamoto KM**. Cell Cycle Regulation by p53 Cdc During Myelopoiesis. Accepted for poster presentation at the American Society of Hematology meeting, December 1996, Orlando, FL.
27. Lin M, Weinstein, and **Sakamoto KM**. The Role of p53 Cdc in Cell Proliferation. Poster presentation at the Keystone Symposia on Growth Control. Keystone, Colorado January 1, 1997.
28. Kwon EM, Lee J H-J, Wong A, and **Sakamoto, KM**. GM-CSF Signaling Pathways Lead to Activation of CREB in myeloid cells. Poster presentation at the Keystone Symposia on Hematopoiesis. Tamarron, Colorado. February, 1997.
29. Mora-Garcia P and **Sakamoto KM**. The Molecular Regulation of G-CSF Induced Myeloid Cell Proliferation and Differentiation. Poster presentation at the Keystone Symposia on Hematopoiesis, Tamarron, Colorado. February, 1997.
30. **Sakamoto KM** and Weinstein J. Increased expression of p53 Cdc in myeloid cells inhibits granulocyte differentiation and accelerates apoptosis. Poster presentation at AACR, San Diego California. April, 1997.
31. Kwon EM, Raines MA and **Sakamoto KM**. GM-CSF Induces Phosphorylation of CREB Through Activation of pp90rsk in Myeloid Cells. Abstract presented at the Society for Pediatric Research by EM Kwon, April 1997.^
32. Kwon EM, Raines MA and **Sakamoto KM**. GM-CSF activates pp90RSK in Myeloid Cells Stimulated with GM-CSF. Abstract presented at the American Society of Hematology by EM Kwon, December 1997.^
33. Lin M, Weinstein, and **Sakamoto KM**. The Role of p53 Cdc in Cell Proliferation. Poster presentation at the American Society of Hematology. December 1997.
- *34. Wang CS, Mendoza MJ, Braun J, and **KM Sakamoto**. Differential Expression of a Novel 50kD Protein in Low- versus High-Grade Murine B-Cell Lymphomas. Abstract presented at the Western Society for Pediatric Research, Carmel. February 1998.
35. Lin M, Weinstein, and **Sakamoto KM**. The Role of p53 Cdc in during G1/S Transition. Poster presentation at the Keystone Symposia on Cell Cycle, Keystone, Colorado. March 1998.

36. Wang CS, Mendoza MJ, Braun J, and KM Sakamoto. Differential Expression of a novel 50kD Protein in Low- versus High-Grade Murine B-Cell Lymphomas. Poster presentation at Keystone Symposia on Cell Cycle, Keystone, Colorado. March 1998.
37. Sakamoto, KM. Invited participant at the Gordon Research Conference in Molecular Genetics; Newport, Rhode Island, July 1998.
38. Rolli M, Neininger A, Kotiyarov A, Sakamoto K, and M Gaestel. Egr-1 expression is regulated by the p38 MAP kinase Pathway Independent of MAPKAP-K2. 10th International Conference on Second messengers and Phosphoproteins, July 1998.
39. Mora-Garcia P and Sakamoto KM. G-CSF regulates myeloid cell proliferation through activation of SRE-binding proteins. American Society for Hematology, Miami Beach FL 1998. Abstract accepted for poster presentation.
40. Mora-Garcia P and KM Sakamoto. G-CSF Regulates Myeloid Cell Proliferation Through Activation of SRE-Binding Proteins. Oral Presentation at the Western Society for Pediatrics meeting in Carmel, CA 1999.^
41. Kwon EM, Raines MA, and KM Sakamoto. Granulocyte Macrophage-Colony Stimulating Factor Induces cAMP response element binding protein phosphorylation through a pp90R SK activated pathway in myeloid cells. Oral Presentation at the Western Society for Pediatrics meeting in Carmel, CA 1999.^
42. Lin M, Kao C, Weinstein J, and KM Sakamoto. P53Cdc overexpression results in premature cell cycle transition from G1 to S phase. Oral Presentation at the Western Society for Pediatrics meeting in Carmel, CA 1999.^
43. KM Sakamoto. "GM-CSF Induces pp90RSK1 Activation and CREB Phosphorylation in Myeloid Leukemic cells". NIH/NCI Workshop on "Serine/Threonine Kinases in Cytokine Signal Transduction," Invited speaker May 30 and 31, 1999.
44. ¹H. Hsu, ²N.G. Rainov, ¹F. Sun, ³K.M. Sakamoto, and ¹M.A. Spear. 4-Ipomeanol (4-IM) prodrug activity in cells carrying the p450 CYP4B1 transgene under an EGR1 promoter induced with ionizing radiation. Am. Soc. Ther. Rad. Onc, 1999.
45. Dai W, Wu H, Lan Z, Li W, Wu S, Weinstein J, KM Sakamoto. BUBR1 interacts with and phosphorylates p53Cdc/hCdc20. Cold Spring Harbor Meeting, "Cell Cycle," May 2000.
46. Sakamoto KM, Crews C and RJ Deshaies. A novel approach to target proteins for proteolysis. Accepted for poster presentation. Keystone Symposium on Cell Cycle, Taos NM, January 2001.
47. Sakamoto KM, Crews C, Kumagai A, and RJ Deshaies. A novel approach to treat cancer. Accepted for poster presentation. Oncogenomics Meeting, Tucson AZ, January, 2001.
48. Deshaies RJ, Sakamoto KM, Seol JH, Verma R. Prospecting at the Cross-roads of ubiquitin-dependent proteolysis and cell cycle control. FASEB meeting, Orlando, FL, 2001.^

49. Crans HC, Landaw EM, Bhatia S, and KM Sakamoto. CREB as a prognostic marker in Acute Leukemia. Accepted for poster presentation, American Society of Hematology meeting, Orlando, FA, 2001.
50. Countouriotis A, Landaw EM, Moore TB, and KM Sakamoto. CREB expression in Acute Leukemia. Accepted for poster presentation and Pediatric Resident Travel Award, A. Countouriotis, Society for Pediatric Research/American Society of Pediatric Hematology/Oncology, May 2002.
51. Mora-Garcia P, Wei J, and KM Sakamoto. G-CSF Signaling induces Stabilization of Fli-1 protein in Myeloid Cells. American Society for Hematology, Philadelphia, PA, December 2002.
- *52. Countouriotis AM, Landaw EM, Moore TB, Sakamoto KM. Comparison of bone marrow aspirates and biopsies in pediatric patients with acute lymphoblastic leukemia. Western Society for Pediatric Research, Carmel, CA. January 2003
- *53. Cheng JC, Crans-Vargas HN, Moore TB, and KM Sakamoto. Aberrant CREB expression in Patients with Acute leukemia. Western Society for Pediatric Research. Carmel, CA. January 2003.
54. Countouriotis AM, Landaw EM, Moore TB, KM Sakamoto. Comparison of bone marrow aspirates and biopsies in pediatric patients with acute lymphoblastic leukemia. Society for Pediatric Research/ASPHO, Seattle, WA. January 2003.
55. Cheng JC, Crans-Vargas HN, Moore TB, and KM Sakamoto. Aberrant CREB expression in Patients with Acute leukemia. Western Society for Pediatric Research. Carmel, CA. January 2003. Won the SPR Resident's Research Award.
- *56. Shankar DB, Cheng J, Headley V, Pan R, Countouriotis A, and KM Sakamoto. CREB is aberrantly expressed in acute myeloid leukemias and regulates myelopoiesis in vitro and in vivo. American Society for Hematology, San Diego, CA. December 2003.
- *57. Shankar DB, Landaw EM, Rao N, Moore TB, and KM Sakamoto. CREB is amplified in AML blasts and is associated with an increased risk of relapse and decreased event-free survival. Oral presentation, American Society for Hematology, San Diego, CA. December 2004.
58. Shankar DB, Kinjo K, Cheng JC, Esparza S, Federman N, Moore TB, and KM Sakamoto. Cyclin A is a target gene of activated CREB downstream of GM-CSF signaling that regulates normal and malignant myelopoiesis. Poster presentation, American Society for Hematology, San Diego, CA. December 2004.
59. Kinjo K, Shankar DB, Cheng JC, Esparza S, Federman N, Moore TB, and KM Sakamoto. CREB overexpression in vivo results in increased proliferation, blast transformation, and earlier engraftment of myeloid progenitor cells. Poster presentation, American Society for Hematology, San Diego, CA. December 2004.

- *60. Kinjo K, Shankar DB, Moore TB, and KM Sakamoto. CREB Regulates hematopoietic progenitor cell proliferation and myeloid engraftment. (AFMR Scholar Award and WSC Travel Award Winner). WSPR, Carmel, CA, February, 2005.
- *61. Menzel LP, Hummerickhouse R, Hagey A, Shah NP, Shankar DB, Moore TB, and KM Sakamoto. Analysis of a targeted receptor tyrosine kinase inhibitor in the treatment of acute myelogenous leukemia. WSPR, Carmel, CA, February, 2005.
- *62. Shankar DB, Chang J, Parcels B, Sandoval S, Li J, Wei R, Tapang P, Davidsen SK, Albert DH, Glaser KB, Moore TB, and KM Sakamoto. The Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces Apoptosis of AML cells both *in vitro* and *in vivo*. Accepted for an oral presentation at the American Society for Hematology; Atlanta GA, December 2005.
- *63. Shankar DB, Kinjo K, Chang J, and KM Sakamoto. CREB Transgenic Mice Develop Myeloproliferative Disease/Myelodysplastic Syndrome after a Prolonged Latency. Accepted for an oral presentation, American Society for Hematology, Atlanta GA, December 2005.
- *64. Parcels BW, Ikeda AK, Moore TB, Glaser KB, and KM Sakamoto. The Multi-Targeted Receptor Tyrosine Kinase Inhibitor ABT-869 Induces Apoptosis in Baf3 cells expressing the FLT3 Internal Tandem Duplication Mutation. Accepted for an oral presentation, WSPR, Carmel, CA. February 2006.
- *65. Simms-Waldrip T, Hernandez J, Shankar DB, Moore TB, Shoemaker A, and KM Sakamoto. Targeting Bcl-2 in acute myeloid leukemia cells. Accepted for an oral presentation, WSPR Carmel, CA. February 2006.
- *66. Rodriguez-Gonzalez A, Kim KB, Crews CM, Deshaies RJ, and KM Sakamoto. Development of Protacs to target the estrogen receptor for ubiquitination and degradation in breast cancer cells. Accepted for an oral presentation. AACR meeting, Washington DC, April 2006.
67. Francisco Martinez F, Jimenez F, Machuca C, Villegas H, and KM Sakamoto. Transcriptional activation of krox-1 induced by sexual hormones in osteosarcoma cells: Accepted for a poster presentation. American Society for Gene Therapy Baltimore, Maryland. May 2006.
68. Cheng JC, Shankar D, and KM Sakamoto. Requirement of CREB in Normal and Malignant Hematopoiesis. Accepted for poster presentation. American Society for Hematology, Orlando FL, December 2006.
69. Esparza SE, Shankar DB, and KM Sakamoto. Identification of Meis1 as a Target of CREB in Myeloid Leukemogenesis. Accepted for poster presentation. American Society for Hematology, Orlando FL, December 2006.
70. Sandoval S, Shankar DB, and KM Sakamoto. Acceleration of Leukemogenesis in CREB Transgenic mice by Retroviral Insertional Mutagenesis. American Society of Hematology, Orlando FL, December 2006.

71. Rodriguez-Gonzalez A, Ch'ng JH, Ikeda A, Lin T, Bahrami B, Mazitschek R, Bradner JE, Fu C, and KM Sakamoto. Targeting Histone Deacetylase 6 and the Aggresome Pathway in Acute Lymphoblastic Leukemia Cells. Accepted for poster presentation. American Society of Hematology, Atlanta, GA, December 2007.
72. Ikeda A, Judelson D, Li J, Wei RQ, Tapang P, Davidsen SK, Albert D, Glaser KB, Fu C, and KM Sakamoto. Inhibiting FLT3 phosphorylation and signaling in AML. Accepted for poster presentation. American Society of Hematology, Atlanta, GA, December 2007.
73. Cheng JC, Judelson D, Kinjo K, Chang J, Landaw EM, and KM Sakamoto. CREB Plays a Critical Role in the Regulation of Normal and Malignant Hematopoiesis. Accepted for poster presentation. American Society of Hematology, Atlanta, GA, December 2007.
74. Hernandez J, Li J, Wei RQ, Tapang P, Davidsen SK, Albert DH, Marcotte PA, Glaser KB, Fu C, and KM Sakamoto. Multi-Targeted Receptor Tyrosine Kinase Inhibitor; ABT-869, Induces apoptosis and Inhibition of Proliferation of Ba/F3 FLT-3 ITD mutant cells. Accepted for poster presentation. American Society of Hematology, Atlanta, GA, December 2007.
- *75. Danilova N, Sakamoto KM, and S Lin. Imbalance of p53 family members as a new target of therapeutics for treatment of Diamond Blackfan Anemia. Accepted for oral presentation. American Society of Hematology, Atlanta, GA, December 2007.
76. Ikeda AK, Judelson DR, Federman N, Li J, Wei RQ, Tapang P, Davidsen SK, Albert DH, Glaser KB, Landaw E, and KM Sakamoto. ABT-869, a Multi-targeted Receptor Tyrosine Kinase Inhibitor, Suppresses Proliferation of Ewing's Sarcoma by inhibiting the PDGFR and c-Kit Pathways. Accepted for poster presentation. American Society of Pediatric Hematology-Oncology meeting, Cincinnati Ohio, May 2008.
77. Hernandez JE, Zape JP, Glaser KB, Fu C, and KM Sakamoto. Multi-targeted receptor tyrosine kinase inhibitor, ABT-869, induces apoptosis and suppresses proliferation of Ba/F3 FLT3-ITD mutant cells in vitro and in vivo through inhibition of FLT3 and AKT. American Society of Hematology meeting, San Francisco, CA, December 2008.
78. Danilova N, Morimoto K, KM Sakamoto, and S Lin. Aberrant p53 signaling pathways in RPL11 mutant zebrafish. American Society of Hematology meeting, San Francisco, CA, December 2008.
79. Rodriguez-Gonzalez A, Simms-Waldrup T, Ikeda A, Lin T, Ch'ng J, Travis B, Aldana Masangkay GI, Mazitschek R, Bradner JE, Fu C, and KM Sakamoto. Tubacin, an inhibitor of HDAC6, induces apoptosis of ALL cells in vitro and in vivo through a Na/K+ ATPase-dependent pathway. American Society of Hematology meeting, San Francisco, CA, December 2008.

80. Hernandez J, Zape JP, Glaser KB, Fu C, and KM Sakamoto. ABT-869, a multi-targeted receptor tyrosine kinase inhibitor induces apoptosis and suppresses proliferation of Ba/F3 FLT3-ITD mutant cells in vitro and in vivo through inhibition of FLT3 and AKT. Abstract accepted for poster presentation. American Association for Cancer Research, April 2009, Denver, Colorado.

*oral presentation of abstract